LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE ORGANOMETALLIC COMPOUND

Information

  • Patent Application
  • 20230322831
  • Publication Number
    20230322831
  • Date Filed
    November 02, 2022
    2 years ago
  • Date Published
    October 12, 2023
    a year ago
Abstract
Provided is a light-emitting device including an organometallic compound represented by Formula 1-1 or 1-2, an electronic apparatus including the light-emitting device, and the organometallic compound represented by Formula 1-1 or 1-2, wherein Formulae 1-1 and 1-2 are respectively the same as those described in the present specification.
Description
CROSS-REFERENCE TO RELATED APPLICATION

This application claims priority to and the benefit of Korean Patent Application No. 10-2021-0152569, filed on Nov. 8, 2021, in the Korean Intellectual Property Office, the entire content of which is hereby incorporated by reference.


BACKGROUND
1. Field

One or more embodiments of the present disclosure relate to a light-emitting device including an organometallic compound, an electronic apparatus including the light-emitting device, and the organometallic compound.


2. Description of the Related Art

Light-emitting devices are self-emissive devices that have wide viewing angles, high contrast ratios, short response times, and excellent characteristics in terms of brightness, driving voltage, and response speed.


Light-emitting devices may include a first electrode on a substrate, and a hole transport region, an emission layer, an electron transport region, and a second electrode sequentially stacked on the first electrode. Holes provided from the first electrode may move toward the emission layer through the hole transport region, and electrons provided from the second electrode may move toward the emission layer through the electron transport region. Carriers, such as holes and electrons, recombine in the emission layer to produce excitons. These excitons transition from an excited state to a ground state to thereby generate light.


SUMMARY

Provided are a light-emitting device including an organometallic compound, an electronic apparatus including the light-emitting device, and the organometallic compound.


Additional aspects of embodiments will be set forth in part in the description which follows and, in part, will be apparent from the description, or may be learned by practice of the presented embodiments of the disclosure.


According to one or more embodiments, provided is a light-emitting device including:

  • a first electrode,
  • a second electrode facing the first electrode, and
  • an interlayer between the first electrode and the second electrode and including an emission layer, and
  • an organometallic compound represented by Formula 1-1 or 1-2.
  • embedded image - Formula 1-1
  • embedded image - Formula 1-2


In Formulae 1-1 and 1-2,

  • M may be platinum (Pt), palladium (Pd), copper(Cu), silver (Ag), gold (Au), rhodium (Rh), ruthenium (Ru), osmium (Os), titanium (Ti), zirconium (Zr), hafnium (Hf), europium (Eu), terbium (Tb), or thulium (Tm),
  • ring CY1 to ring CY3 may each independently be a C5-C30 carbocyclic group or a C1-C30 heterocyclic group,
  • X1 to X3 may each independently be C or N,
  • X21 may be C,
  • Y1 may be C(Z1) or N,
  • Y2 may be C(Z2) or N,
  • Y3 may be C(Z3) or N,
  • Y4 may be C(Z4) or N,
  • Y5 may be C(Z5) or N,
  • Y6 may be C(Z6) or N,
  • Y7 may be C(Z7) or N,
  • Y8 may be C(Z8) or N,
  • L1 to L3 may each independently be a single bond, *—C(R1a)(R1b)—*’, *—C(R1a)═*’, *═C(R1a)—*’, *—C(R1a)═C(R1b)—*’, *—C(═O)—*’, *—C(═S)—*’, *—C≡C—*’, *—B(R1a)—*’, *—N(R1a)—*’, *—O—*’, *—P(R1a)—*’, *—Si(R1a)(R1b)—*’, *—P(═O)(R1a)—*’, *—S—*’, *—S(═O)—*’, *—S(═O)2—*’, or *—Ge(R1a)(R1b)—*’, and * and *’ may each indicate a binding site to a neighboring atom,
  • n1 to n3 may each independently be an integer from 1 to 5,
  • R1 to R3, Z1 to Z8, R1a and R1b may each independently be hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C60 alkyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkenyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkynyl group unsubstituted or substituted with at least one R10a, a C1-C60 alkoxy group unsubstituted or substituted with at least one R10a, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, a C6-C60 aryloxy group unsubstituted or substituted with at least one R10a, a C6-C60 arylthio group unsubstituted or substituted with at least one R10a, —C(Q1)(Q2)(Q3), —Si(Q1)(Q2)(Q3), —N(Q1)(Q2), —B(Q1)(Q2), —C(═O)(Q1), —S(═O)2(Q1), or —P(═O)(Q1)(Q2),
  • a1 to a3 may each independently be an integer from 0 to 10,
  • embedded image
  • in Formulae 1-1 and 1-2 may indicate a single bond or a double bond,
  • Z1 and Z2 may optionally be bonded together to form a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,
  • Z3 and Z4 may optionally be bonded together to form a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,
  • Z5 and Z6 may optionally be bonded together to form a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,
  • Z7 and Z8 may optionally be bonded together to form a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,
  • R10a may be:
    • deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, or a nitro group,
  • a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, or a C1-C60 alkoxy group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C3-C60 carbocyclic group, a C1-C60 heterocyclic group, a C6-C60 aryloxy group, a C6-C60 arylthio group, -Si(Q11)(Q12)(Q13), -N(Q11)(Q12), -B(Q11)(Q12), —C(═O)(Q11), —S(═O)2(Q11), —P(═O)(Q11)(Q12), or any combination thereof,
  • a C3-C60 carbocyclic group, a C1-C60 heterocyclic group, a C6-C60 aryloxy group, or a C6-C60 arylthio group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a C3-C60 carbocyclic group, a C1-C60 heterocyclic group, a C6-C60 aryloxy group, a C6-C60 arylthio group, —Si(Q21)(Q22)(Q23), —N(Q21)(Q22), —B(Q21)(Q22), —C(═O)(Q21), —S(═O)2(Q21), —P(═O)(Q21)(Q22), or any combination thereof, or
  • —Si(Q31)(Q32)(Q33), —N(Q31)(Q32), —B(Q31)(Q32), —C(═O)(Q31), —S(═O)2(Q31), or —P(═O)(Q31)(Q32), and
  • Q1 to Q3, Q11 to Q13, Q21 to Q23, and Q31 to Q33 may each independently be hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, or a C3-C60 carbocyclic group or a C1-C60 heterocyclic group, each unsubstituted or substituted with deuterium, —F, a cyano group, a C1-C60 alkyl group, a C1-C60 alkoxy group, a phenyl group, a biphenyl group, or any combination thereof.


According to one or more embodiments, an electronic apparatus including the light-emitting device is provided.


According to one or more embodiments, the organometallic compound represented by Formula 1-1 or 1-2 is provided.





BRIEF DESCRIPTION OF THE DRAWINGS

The above and other aspects and features of certain embodiments of the disclosure will be more apparent from the following description taken in conjunction with the accompanying drawings, in which:



FIG. 1 shows a schematic cross-sectional view of a structure of a light-emitting device according to an embodiment;



FIG. 2 shows a schematic cross-sectional view of a structure of an electronic apparatus according to an embodiment; and



FIG. 3 shows a schematic cross-sectional view of a structure of an electronic apparatus according to another embodiment.





DETAILED DESCRIPTION

Reference will now be made in more detail to embodiments, examples of which are illustrated in the accompanying drawings, wherein like reference numerals refer to like elements throughout. In this regard, the present embodiments may have different forms and should not be construed as being limited to the descriptions set forth herein. Accordingly, the embodiments are merely described below, by referring to the figures, to explain aspects of embodiments of the present description. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items. Throughout the disclosure, the expression “at least one of a, b or c” indicates only a, only b, only c, both a and b, both a and c, both b and c, all of a, b, and c, or variations thereof.


A light-emitting device may include: a first electrode; a second electrode facing the first electrode; an interlayer between the first electrode and the second electrode and including an emission layer; and an organometallic compound represented by Formula 1-1 or 1-2:




embedded image - Formula 1-1




embedded image - Formula 1-2


wherein M in Formulae 1-1 and 1-2 may be platinum (Pt), palladium (Pd), copper(Cu), silver (Ag), gold (Au), rhodium (Rh), ruthenium (Ru), osmium (Os), titanium (Ti), zirconium (Zr), hafnium (Hf), europium (Eu), terbium (Tb), or thulium (Tm).


In an embodiment, M may be platinum (Pt).


Ring CY1 to ring CY3 in Formulae 1-1 and 1-2 may each independently be a C5-C30 carbocyclic group or a C1-C30 heterocyclic group.


In an embodiment, ring CY1 to ring CY3 may each independently be a benzene group, a naphthalene group, an anthracene group, a phenanthrene group, a triphenylene group, a pyrene group, a chrysene group, a cyclopentadiene group, a 1,2,3,4-tetrahydronaphthalene group, a thiophene group, a furan group, an indole group, a benzoborole group, a benzophosphole group, an indene group, a benzosilole group, a benzogermole group, a benzothiophene group, a benzoselenophene group, a benzofuran group, a carbazole group, a dibenzoborole group, a dibenzophosphole group, a fluorene group, a dibenzosilole group, a dibenzogermole group, a dibenzothiophene group, a dibenzoselenophene group, a dibenzofuran group, a dibenzothiophene 5-oxide group, a 9H-fluorene-9-one group, a dibenzothiophene 5,5-dioxide group, an azaindole group, an azabenzoborole group, an azabenzophosphole group, an azaindene group, an azabenzosilole group, an azabenzogermole group, an azabenzothiophene group, an azabenzoselenophene group, an azabenzofuran group, an azacarbazole group, an azadibenzoborole group, an azadibenzophosphole group, an azafluorene group, an azadibenzosilole group, an azadibenzogermole group, an azadibenzothiophene group, an azadibenzoselenophene group, an azadibenzofuran group, an azadibenzothiophene 5-oxide group, an aza-9H-fluorene-9-one group, an azadibenzothiophene 5,5-dioxide group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a phenanthroline group, a pyrrole group, a pyrazole group, an imidazole group, a triazole group, an oxazole group, an iso-oxazole group, a thiazole group, an isothiazole group, an oxadiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a benzoxazole group, a benzothiazole group, a benzoxadiazole group, a benzothiadiazole group, a 5,6,7,8-tetrahydroisoquinoline group, or a 5,6,7,8-tetrahydroquinoline group.


In an embodiment, ring CY1 may be a benzene group, a naphthalene group, or a pyridine group.


In an embodiment, ring CY2 and ring CY3 may each independently be a C1-C30 heterocyclic group.


In an embodiment, ring CY2 and ring CY3 may include at least one nitrogen.


In an embodiment, ring CY2 may be an indole group or a carbazole group.


In an embodiment, ring CY3 may be a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a phenanthroline group, a pyrrole group, a pyrazole group, an imidazole group, a triazole group, a benzopyrazole group, a benzimidazole group, or a benzothiazole group.


In an embodiment, a group represented by




embedded image


in Formulae 1-1 and 12 may be any one of groups represented by Formulae CY1 (1) to CY1(20):




embedded image - (1)




embedded image - (2)




embedded image - (3)




embedded image - CY1 (4)




embedded image - (5)




embedded image - (6)




embedded image - (7)




embedded image - (8)




embedded image - (9)




embedded image - (10)




embedded image - (11)




embedded image - (12)




embedded image - (13)




embedded image - (14)




embedded image - (15)




embedded image - (16)




embedded image - (17)




embedded image - (18)




embedded image - (19)




embedded image - (20)


wherein, in Formulae CY1(1) to CY1(20),

  • R11 to R13 may each independently be deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C60 alkyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkenyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkynyl group unsubstituted or substituted with at least one R10a, a C1-C60 alkoxy group unsubstituted or substituted with at least one R10a, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, a C6-C60 aryloxy group unsubstituted or substituted with at least one R10a, a C6-C60 arylthio group unsubstituted or substituted with at least one R10a, —C(Q1)(Q2)(Q3), —Si(Q1)(Q2)(Q3), —N(Q1)(Q2), —B(Q1)(Q2), —C(═O)(Q1), —S(═O)2(Q1), or —P(═O)(Q1)(Q2),
  • *, *’, and *” each indicate a binding site to a neighboring atom, and
  • X1, R10a, and Q1 to Q3 are respectively the same as those described in the present specification.


In an embodiment, R11 to R13 may each independently be:

  • deuterium, —F, —Cl, —Br, —I, or a cyano group;
  • —CH3, —CD3, —CD2H, —CDH2, —CH2CH3, —CH2CD3, —CH2CD2H, —CH2CDH2, —CHDCH3, —CHDCD2H, —CHDCDH2, —CHDCD3, —CD2CD3, —CD2CD2H, or —CD2CDH2;
  • an n-propyl group, an iso-propyl group, an n-butyl group, an isobutyl group, a sec-butyl group, or a tert-butyl group, each unsubstituted or substituted with deuterium; or
  • a phenyl group, a biphenyl group, a terphenyl group, or a naphthalene, each unsubstituted or substituted with deuterium, —CH3, —CD3, —CD2H, —CDH2, —CH2CH3, —CH2CD3, —CH2CD2H, —CH2CDH2, —CHDCH3, —CHDCD2H, —CHDCDH2, —CHDCD3, —CD2CD3, —CD2CD2H or —CD2CDH2, an n-propyl group, an iso-propyl group, an n-butyl group, an isobutyl group, a sec-butyl group, and a tert-butyl group.


In an embodiment, a group represented by




embedded image


in Formulae 1-1 and 1-2 may be any one of groups represented by Formulae CY2(1) to CY2(11):




embedded image - (1)




embedded image - (2)




embedded image - (3)




embedded image - (4)




embedded image - (5)




embedded image - (6)




embedded image - (7)




embedded image - (8)




embedded image - (9)




embedded image - (10)




embedded image - (11)




  • wherein, in Formulae CY2(1) to CY2(11),

  • b1 may be an integer from 0 to 3,

  • b2 may be an integer from 0 to 2,

  • b3 may be an integer from 0 to 6,

  • b4 may be an integer from 0 to 5,

  • *, *’, and *” each indicate a binding site to a neighboring atom, and

  • X2 and R2 are respectively the same as those described in the present specification.



In an embodiment, a group represented by Formula CY2(1) may be any one of groups represented by Formulae CY2(1)-1 to CY2(1)-7:




embedded image - CY2(1)-1




embedded image - CY2(1)-2




embedded image - CY2(1)-3




embedded image - CY2(1)-4




embedded image - CY2(1)-5




embedded image - CY2(1)-6




embedded image - CY2(1)-7


wherein, in Formulae CY2(1)-1 to CY2(1)-7,

  • R21 to R23 may each independently be deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C60 alkyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkenyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkynyl group unsubstituted or substituted with at least one R10a, a C1-C60 alkoxy group unsubstituted or substituted with at least one R10a, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, a C6-C60 aryloxy group unsubstituted or substituted with at least one R10a, a C6-C60 arylthio group unsubstituted or substituted with at least one R10a, —C(Q1)(Q2)(Q3), —Si(Q1)(Q2)(Q3), —N(Q1)(Q2), —B(Q1)(Q2), —C(═O)(Q1), —S(═O)2(Q1), or —P(═O)(Q1)(Q2),
  • X2 is the same as described in the present specification,
  • *, *’, and *” each indicate a binding site to a neighboring atom.


In an embodiment, R21 to R23 may each independently be:

  • deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C20 alkyl group, or a C1-C20 alkoxy group;
  • a C1-C20 alkyl group or a C1-C20 alkoxy group, each substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, a C1-C10 alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, or any combination thereof;
  • a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a C1-C10 alkylphenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, a benzoisothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a 9,10-dihydroacridinyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an azacarbazolyl group, an azadibenzofuranyl group, an azadibenzothiophenyl group, an azafluorenyl group, or an azadibenzosilolyl group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, a C1-C20 alkyl group, a C1-C20 alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a C1-C10 alkylphenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, a benzoisothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a 9,10-dihydroacridinyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, —Si(Q31)(Q32)(Q33), —N(Q31)(Q32), —B(Q31)(Q32), —P(Q31)(Q32), —C(═O)(Q31), —S(═O)2(Q31), —P(═O)(Q31)(Q32), or any combination thereof; or
  • —Si(Q1)(Q2)(Q3), —N(Q1)(Q2), —B(Q1)(Q2), —C(═O)(Q1), —S(═O)2(Q1), or —P(═O)(Q1)(Q2), and
  • Q1 to Q3 and Q31 to Q33 may each independently be:
  • —CH3, —CD3, —CD2H, —CDH2, —CH2CH3, —CH2CD3, —CH2CD2H, —CH2CDH2, —CHDCH3, —CHDCD2H, —CHDCDH2, —CHDCD3, —CD2CD3, —CD2CD2H, or —CD2CDH2; or
  • an n-propyl group, an iso-propyl group, an n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazinyl group, or a triazinyl group, each unsubstituted or substituted with at least one of deuterium, a C1-C10 alkyl group, a phenyl group, a biphenyl group, a pyridinyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazinyl group, and a triazinyl group.


In an embodiment, a group represented by




embedded image


in Formula 1-1 may be any one of groups represented by Formulae CY3(1) to CY3(14):




embedded image - (1)




embedded image - (2)




embedded image - (3)




embedded image - (4)




embedded image - (5)




embedded image - (6)




embedded image - (7)




embedded image - (8)




embedded image - (9)




embedded image - (10)




embedded image - (11)




embedded image - (12)




embedded image - (13)




embedded image - (14)




  • wherein, in Formulae CY3(1) to CY3(14),

  • R31 to R34 may each independently be deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C60 alkyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkenyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkynyl group unsubstituted or substituted with at least one R10a, a C1-C60 alkoxy group unsubstituted or substituted with at least one R10a, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, a C6-C60 aryloxy group unsubstituted or substituted with at least one R10a, a C6-C60 arylthio group unsubstituted or substituted with at least one R10a, —C(Q1)(Q2)(Q3), —Si(Q1)(Q2)(Q3), —N(Q1)(Q2), —B(Q1)(Q2), —C(═O)(Q1), —S(═O)2(Q1), or —P(═O)(Q1)(Q2),

  • * and *’ each indicate a binding site to a neighboring atom, and

  • R10a and Q1 to Q3 are respectively the same as those described in the present specification.



In an embodiment, R31 to R33 may each independently be:

  • deuterium, —F, —Cl, —Br, —I, or a cyano group;
  • —CH3, —CD3, —CD2H, —CDH2, —CH2CH3, —CH2CD3, —CH2CD2H, —CH2CDH2, —CHDCH3, —CHDCD2H, —CHDCDH2, —CHDCD3, —CD2CD3, —CD2CD2H, or —CD2CDH2;
  • an n-propyl group, an iso-propyl group, an n-butyl group, an isobutyl group, a sec-butyl group, or a tert-butyl group, each unsubstituted or substituted with deuterium; or
  • a phenyl group, a biphenyl group, a terphenyl group, or a naphthalene, each unsubstituted or substituted with deuterium, —CH3, —CD3, —CD2H, —CDH2, —CH2CH3, —CH2CD3, —CH2CD2H, —CH2CDH2, —CHDCH3, —CHDCD2H, —CHDCDH2, —CHDCD3, —CD2CD3, —CD2CD2H or —CD2CDH2, an n-propyl group, an iso-propyl group, an n-butyl group, an isobutyl group, a sec-butyl group, and a tert-butyl group.


X1 to X3 in Formulae 1-1 and 1-2 may each independently be C or N.


In an embodiment, X1 and X2 may each be C, and X3 may be N.


X21 in Formula 1-1 and X21 in Formula 1-2 may each be C.


In Formulae 1-1 and 1-2,

  • Y1 may be C(Z1) or N,
  • Y2 may be C(Z2) or N,
  • Y3 may be C(Z3) or N,
  • Y4 may be C(Z4) or N,
  • Y5 may be C(Z5) or N,
  • Y6 may be C(Z6) or N,
  • Y7 may be C(Z7) or N, and
  • Y8 may be C(Z8) or N.


In an embodiment, in Formulae 1-1 and 1-2,

  • Y1 may be C(Z1),
  • Y2 may be C(Z2),
  • Y3 may be C(Z3),
  • Y4 may be C(Z4),
  • Y5 may be C(Z5),
  • Y6 may be C(Z6),
  • Y7 may be C(Z7), and
  • Y3 may be C(Z8).




embedded image


in Formulae 1-1 and 1-2 indicates a single bond or a double bond.


A group represented by




embedded image




embedded image


in Formulae 1-1 and 1-2 may be any one of groups represented by Formulae CYN(1) to CYN(21):




embedded image - (1)




embedded image - (2)




embedded image - (3)




embedded image - (4)




embedded image - (5)




embedded image - (6)




embedded image - (7)




embedded image - (8)




embedded image - (9)




embedded image - (10)




embedded image - (11)




embedded image - (12)




embedded image - (13)




embedded image - (14)




embedded image - (15)




embedded image - (16)




embedded image - (17)




embedded image - (18)




embedded image - (19)




embedded image - (20)




embedded image - (21)




  • wherein, in Formulae CYN(1) to CYN(21),

  • Z11 to Z16 may each independently be deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C60 alkyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkenyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkynyl group unsubstituted or substituted with at least one R10a, a C1-C60 alkoxy group unsubstituted or substituted with at least one R10a, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, a C6-C60 aryloxy group unsubstituted or substituted with at least one R10a, a C6-C60 arylthio group unsubstituted or substituted with at least one R10a, —C(Q1)(Q2)(Q3), —Si(Q1)(Q2)(Q3), —N(Q1)(Q2), —B(Q1)(Q2), —C(═O)(Q1), —S(═O)2(Q1), or —P(═O)(Q1)(Q2),

  • b15 and b16 may each independently be an integer from 0 to 4,

  • Y11 to Y18 may each independently be C or N, and

  • R10a and Q1 to Q3 are respectively the same as those described in the present specification.



In an embodiment, Z11 to Z16 may each independently be deuterium, —F, —Cl, —Br, —I, a cyano group, a C1-C60 alkyl group unsubstituted or substituted with at least one R10a, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, or —Si(Q1)(Q2)(Q3).


In an embodiment, Z11 to Z16 may each independently be:

  • deuterium, —F, —Cl, —Br, —I, or a cyano group;
  • —CH3, —CD3, —CD2H, —CDH2, —CH2CH3, —CH2CD3, —CH2CD2H, —CH2CDH2, —CHDCH3, —CHDCD2H, —CHDCDH2, —CHDCD3, —CD2CD3, —CD2CD2H, or —CD2CDH2;
  • an n-propyl group, an iso-propyl group, an n-butyl group, an isobutyl group, a sec-butyl group, or a tert-butyl group, each unsubstituted or substituted with deuterium;
  • a phenyl group, a biphenyl group, a terphenyl group, or a naphthalene, each unsubstituted or substituted with deuterium, —CH3, —CD3, —CD2H, —CDH2, —CH2CH3, —CH2CD3, —CH2CD2H, —CH2CDH2, —CHDCH3, —CHDCD2H, —CHDCDH2, —CHDCD3, —CD2CD3, —CD2CD2H or —CD2CDH2, an n-propyl group, an iso-propyl group, an n-butyl group, an isobutyl group, a sec-butyl group, and a tert-butyl group;
  • or —Si(Q1)(Q2)(Q3).


In an embodiment, Y11 to Y14 may each be C.


In an embodiment,

  • Y11 may be N, and Y12 to Y14 may each be C;
  • Y12 may be N, and Y11, Y13, and Y14 may each be C; or
  • Y14 may be N, and Y11 to Y13 may each be C.


In an embodiment, Y11 and Y14 may each be N, and Y12 and Y13 may each be C.


In an embodiment, Y15 to Y18 may each be C.


In an embodiment,

  • Y15 may be N, and Y16 to Y18 may each be C; or
  • Y18 may be N, and Y15 to Y17 may each be C.


In an embodiment, Y15 and Y18 may each be N, and Y16 and Y17 may each be C.


L1 to L3 in Formulae 1-1 and 1-2 may each independently be a single bond,

  • *—C(R1a)(R1b)—*’, *—C(R1a)═*’, *═C(R1a)—*’, *—C(R1a)═C(R1b)—*’, *—C(═O)—*’, *—C(═S)—*’, *—C═C—*’, *—B(R1a)—*’, *—N(R1a)—*’, *—O—*’, *—P(R1a)—*’, *—Si(R1a)(R1b)—*’, *—P(═O)(R1a)—*’, *—S—*’, *—S(═O)—*’, *—S(═O)2—*’, or *—Ge(R1a)(R1b)—*’, and * and *' each indicate a binding site to a neighboring atom.


In an embodiment, L1 and L3 may each be a single bond.


In an embodiment, L2 may be *—O—*’.


n1 to n3 in Formulae 1-1 and 1-2 may each independently be an integer from 1 to 5.


In an embodiment, n2 may be 1.


R1 to R3, Z1 to Z8, R1a and R1b in Formulae 1-1 and 1-2 may each independently be hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C60 alkyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkenyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkynyl group unsubstituted or substituted with at least one R10a, a C1-C60 alkoxy group unsubstituted or substituted with at least one R10a, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, a C6-C60 aryloxy group unsubstituted or substituted with at least one R10a, a C6-C60 arylthio group unsubstituted or substituted with at least one R10a, —C(Q1)(Q2)(Q3), —Si(Q1)(Q2)(Q3), —N(Q1)(Q2), —B(Q1)(Q2), —C(═O)(Q1), —S(═O)2(Q1), or —P(═O)(Q1)(Q2).


In an embodiment, R1 to R3, Z1 to Z8, R1a and R1b may each independently be:

  • hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C20 alkyl group, or a C1-C20 alkoxy group;
  • a C1-C20 alkyl group or a C1-C20 alkoxy group, each substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, a C1-C10 alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, or any combination thereof;
  • a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a C1-C10 alkylphenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, a benzoisothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a 9,10-dihydroacridinyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an azacarbazolyl group, an azadibenzofuranyl group, an azadibenzothiophenyl group, an azafluorenyl group, or azadibenzosilolyl group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, a C1-C20 alkyl group, a C1-C20 alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a C1-C10 alkylphenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, a benzoisothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a 9,10-dihydroacridinyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, —Si(Q31)(Q32)(Q33), —N(Q31)(Q32), —B(Q31)(Q32), —P(Q31)(Q32), —C(═O)(Q31), —S(═O)2(Q31), —P(═O)(Q31)(Q32), or any combination thereof; or
  • —Si(Q1)(Q2)(Q3), —N(Q1)(Q2), —B(Q1)(Q2), —C(═O)(Q1), —S(═O)2(Q1), or —P(═O)(Q1)(Q2), and
  • Q1 to Q3 and Q31 to Q33 may each independently be:
    • —CH3, —CD3, —CD2H, —CDH2, —CH2CH3, —CH2CD3, —CH2CD2H, —CH2CDH2, —CHDCH3, —CHDCD2H, —CHDCDH2, —CHDCD3, —CD2CD3, —CD2CD2H, or —CD2CDH2; or
  • an n-propyl group, an iso-propyl group, an n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazinyl group, or a triazinyl group, each unsubstituted or substituted with deuterium, a C1-C10 alkyl group, a phenyl group, a biphenyl group, a pyridinyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazinyl group, a triazinyl group, or any combination thereof.


In an embodiment, R1 to R3, Z1 to Z8, R1a and R1b may each independently be:

  • hydrogen, deuterium, —F, —Cl, —Br, —I, a cyano group, a C1-C20 alkyl group;
  • a C1-C20 alkyl group substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a cyano group, a nitro group, a C1-C10 alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, or any combination thereof;
  • a phenyl group, a biphenyl group, a C1-C10 alkylphenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, a benzoisothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a 9,10-dihydro acridinyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an azacarbazolyl group, an azadibenzofuranyl group, an azadibenzothiophenyl group, an azafluorenyl group, or azadibenzosilolyl group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a cyano group, a C1-C20 alkyl group, a phenyl group, a biphenyl group, a C1-C10 alkylphenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzoimidazolyl group, a benzofuranyl group, a benzothiophenyl group, a benzoisothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a 9,10-dihydroacridinyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, —Si(Q31)(Q32)(Q33), —N(Q31)(Q32), —B(Q31)(Q32), or any combination thereof; or
  • —Si(Q1)(Q2)(Q3), —N(Q1)(Q2), or —B(Q1)(Q2), and
  • Q1 to Q3 and Q31 to Q33 may each independently be:
    • —CH3, —CD3, —CD2H, —CDH2, —CH2CH3, —CH2CD3, —CH2CD2H, —CH2CDH2, —CHDCH3, —CHDCD2H, —CHDCDH2, —CHDCD3, —CD2CD3, —CD2CD2H, or —CD2CDH2; or
  • an n-propyl group, an iso-propyl group, an n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazinyl group, or a triazinyl group, each unsubstituted or substituted with deuterium, a C1-C10 alkyl group, a phenyl group, a biphenyl group, a pyridinyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazinyl group, a triazinyl group, or any combination thereof.


In an embodiment, R1 to R3 may each independently be:

  • a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a 2-methylbutyl group, a 2,2-dimethylpropyl group, a 1-ethylpropyl group, or a 1,2-dimethylpropyl group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, or a nitro group; or
  • a phenyl group, a biphenyl group, a naphthyl group, a phenanthrenyl group, an anthracenyl group, a carbazolyl group, or a 9,10-dihydroacridinyl group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a 2-methylbutyl group, a 2,2-dimethylpropyl group, a 1-ethylpropyl group, a 1,2-dimethylpropyl group, a phenyl group, or any combination thereof.
  • Z1 and Z2 may optionally be bonded together to form a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,
  • Z3 and Z4 may optionally be bonded together to form a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,
  • Z5 and Z6 may optionally be bonded together to form a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, and
  • Z7 and Z8 may optionally be bonded together to form a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a.


In an embodiment,


Z1 to Z8 may each independently be:

  • a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a 2-methylbutyl group, a 2,2-dimethylpropyl group, a 1-ethylpropyl group, or a 1,2-dimethylpropyl group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, or a nitro group; or
  • a phenyl group, a biphenyl group, or a naphthyl group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a 2-methylbutyl group, 2,2-dimethylpropyl group, 1-ethylpropyl, 1,2-dimethylpropyl, a phenyl group or any combination thereof,
  • Z1 and Z2 may be bonded together to form a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,
  • Z3 and Z4 may be bonded together to form a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,
  • Z5 and Z6 may be bonded together to form a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, or
  • Z7 and Z8 may be bonded together to form a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a.


In an embodiment, a C3-C60 carbocyclic group and a C1-C60 heterocyclic group, which are formed by bonding Z1 and Z2, Z3 and Z4, Z5 and Z6, or Z7 and Z8 together, may include a 6-membered ring.


In an embodiment,

  • the C3-C60 carbocyclic group may be a phenyl group or a naphthyl group, and
  • the C1-C60 heterocyclic group may be a pyridine, a pyrimidine, or a pyrazine.
  • a1 to a3 in Formulae 1-1 and 1-2 may each independently be an integer from 0 to 10.


In an embodiment, the organometallic compound represented by Formula 1-1 or 1-2 may be any one of Compounds 1 to 80.




embedded image - 1




embedded image - 2




embedded image - 3




embedded image - 4




embedded image - 5




embedded image - 6




embedded image - 7




embedded image - 8




embedded image - 9




embedded image - 10




embedded image - 11




embedded image - 12




embedded image - 13




embedded image - 14




embedded image - 15




embedded image - 16




embedded image - 17




embedded image - 18




embedded image - 19




embedded image - 20




embedded image - 21




embedded image - 22




embedded image - 23




embedded image - 24




embedded image - 25




embedded image - 26




embedded image - 27




embedded image - 28




embedded image - 29




embedded image - 30




embedded image - 31




embedded image - 32




embedded image - 33




embedded image - 34




embedded image - 35




embedded image - 36




embedded image - 37




embedded image - 38




embedded image - 39




embedded image - 40




embedded image - 41




embedded image - 42




embedded image - 43




embedded image - 44




embedded image - 45




embedded image - 46




embedded image - 47




embedded image - 48




embedded image - 49




embedded image - 50




embedded image - 51




embedded image - 52




embedded image - 53




embedded image - 54




embedded image - 55




embedded image - 56




embedded image - 57




embedded image - 58




embedded image - 59




embedded image - 60




embedded image - 61




embedded image - 62




embedded image - 63




embedded image - 64




embedded image - 65




embedded image - 66




embedded image - 67




embedded image - 68




embedded image - 69




embedded image - 70




embedded image - 71




embedded image - 72




embedded image - 73




embedded image - 74




embedded image - 75




embedded image - 76




embedded image - 77




embedded image - 78




embedded image - 79




embedded image - 80


The organometallic compound represented by Formula 1-1 or 1-2 includes a group represented by Formula 1A or 1B among Formulae 1-1 and 1-2.




embedded image - Formula 1A




embedded image - Formula 1B


According to embodiments of the present disclosure, the organometallic compound represented by Formula 1-1 or 1-2 may have improved rigidity of ligands, and thus, exhibit relatively excellent triplet metal to ligand charge transfer (3MLCT) characteristics. Therefore, an electronic device (for example, an organic light-emitting device) having high efficiency and long lifespan may be implemented by using the organometallic compound.


In an embodiment, the organometallic compound represented by Formula 1-1 or 1-2 may have a 3MLCT value of about 10% or more.


Methods of synthesizing the organometallic compound represented by Formula 1-1 or 1-2 may be easily understood to those of ordinary skill in the art by referring to Synthesis Examples and/or Examples described herein.


In an embodiment,

  • the first electrode of the light-emitting device may be an anode,
  • the second electrode of the light-emitting device may be a cathode,
  • the interlayer may further include a hole transport region between the first electrode and the emission layer and an electron transport region between the emission layer and the second electrode layer,
  • the hole transport region may include a hole injection layer, a hole transport layer, an emission auxiliary layer, an electron blocking layer, or any combination thereof, and
  • the electron transport region may include a hole blocking layer, an electron transport layer, an electron injection layer, an electron control layer, or any combination thereof.


In an embodiment, the interlayer of the light-emitting device may include the organometallic compound represented by Formula 1.


In an embodiment, the emission layer of the light-emitting device may include the organometallic compound represented by Formula 1.


In an embodiment, the emission layer may emit blue light. In an embodiment, the emission layer may emit blue light having a maximum emission wavelength of 410 nm to 500 nm, 410 nm to 480 nm, 420 nm to 480 nm, or 430 nm to 470 nm.


In an embodiment, the emission layer of the light-emitting device may include a dopant and a host, and the dopant may include the organometallic compound represented by Formula 1-1 or 1-2. For example, the organometallic compound may serve as a dopant. The emission layer may emit, for example, blue light. The blue light may have a maximum emission wavelength in a range of, for example, about 430 nm to about 470 nm.


In an embodiment, the electron transport region of the light-emitting device may include a hole blocking layer, and the hole blocking layer may include a phosphine oxide-containing compound, a silicon-containing compound, or any combination thereof. In an embodiment, the hole blocking layer may directly contact the emission layer.


In an embodiment, the interlayer in the light-emitting device may include i) a first compound, which is the organometallic compound represented by Formula 1-1 or 1-2; and ii) a second compound including at least one TT electron-deficient nitrogen-containing C1-C60 cyclic group, a third compound including a group represented by Formula 3, a fourth compound capable of emitting delayed fluorescence, or any combination thereof, and the first compound, the second compound, the third compound, and the fourth compound are different from each other:




embedded image - Formula 3




  • wherein ring CY71 and ring CY72 in Formula 3 are each independently a TT electron-rich C3-C60 cyclic group or a pyridine group,

  • X71 in Formula 3 is a single bond, or a linking group including O, S, N, B, C, Si, or any combination thereof,

  • * in Formula 3 indicates a binding site to a neighboring atom in the third compound, and

  • the following compounds may be excluded from the third compound (e.g., the third compound is not either of the following compounds):



  • embedded image - CBP




  • embedded image - mCBP




Further Descriptions of the Second Compound, the Third Compound, and the Fourth Compound

The second compound may include a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, or any combination thereof.


In an embodiment, the light-emitting device may further include at least one of the second compound and the third compound, in addition to the first compound.


In an embodiment, the light-emitting device may further include the fourth compound, in addition to the first compound.


In an embodiment, the light-emitting device may include the first compound, the second compound, the third compound, and the fourth compound.


In an embodiment, the interlayer may include the second compound. The interlayer may further include, in addition to the first compound and the second compound, the third compound, the fourth compound, or any combination thereof.


In an embodiment, a difference between the triplet energy level (eV) of the fourth compound and the singlet energy level (eV) of the fourth compound may be about 0 eV or higher and 0.5 eV or lower (or, about 0 eV or higher and about 0.3 eV or lower).


In an embodiment, the fourth compound may be a compound including at least one cyclic group including boron (B) and nitrogen (N) as ring-forming atoms.


In an embodiment, the fourth compound may be a C8-C60 polycyclic group-containing compound including at least two condensed cyclic groups (e.g., at least one first ring and at least one second ring) that share a boron atom (B).


In an embodiment, the fourth compound may include a condensed ring in which at least one third ring may be condensed together with at least one fourth ring,

  • the third ring may be a cyclopentane group, a cyclohexane group, a cycloheptane group, a cyclooctane group, a cyclopentene group, a cyclohexene group, a cycloheptene group, a cyclooctene group, an adamantane group, a norbornene group, a norobornane group, a bicyclo[1.1.1 ]pentane group, a bicyclo[2.1.1]hexane group, a bicyclo[2.2.2]octane group, a benzene group, a pyridine group, a pyrimidine group, a pyridazine group, a pyrazine group, or a triazine group, and
  • the fourth ring may be a 1,2-azaborinine group, a 1,3-azaborinine group, a 1,4-azaborinine group, a 1,2-dihydro-1,2-azaborinine group, a 1,4-oxaborinine group, a 1,4-thiaborinine group, or a 1,4-dihydroborinine group.


In an embodiment, the interlayer may include the fourth compound. The interlayer may include, in addition to the first compound and the fourth compound, the second compound, the third compound, or any combination thereof.


In an embodiment, the interlayer may include the third compound. In an embodiment, the third compound may not include CBP described herein and a compound represented by mCBP.


The emission layer in the interlayer may include i) the first compound; and ii) the second compound, the third compound, the fourth compound, or any combination thereof.


The emission layer may emit phosphorescence or fluorescence emitted from the first compound. In an embodiment, phosphorescence or fluorescence emitted from the first compound may be blue light.


In an embodiment, the emission layer in the light-emitting device may include the first compound and the second compound, and the first compound and the second compound may form an exciplex.


In an embodiment, the emission layer in the light-emitting device may include the first compound, the second compound, and the third compound, and the second compound and the third compound may form an exciplex.


In an embodiment, the emission layer in the light-emitting device may include the first compound and the fourth compound, and the fourth compound may serve to improve color purity, luminescence efficiency, and/or lifespan characteristics of the light-emitting device.


When at least one compound (for example, the fourth compound) including boron (B) and nitrogen (N) as ring-forming atoms and the organometallic compound represented by Formula 1-1 or 1-2 are included together in a dopant, the organometallic compound represented by Formula 1-1 or 1-2 may serve as a sensitizer. When the organometallic compound represented by Formula 1-1 or 1-2 serves as a sensitizer, energy of excitons generated in the emission layer may be transferred to the organometallic compound, the energy may be transferred from the organometallic compound to another remaining dopant (for example, the fourth compound), and the other remaining dopant may serve as an emitter.


In an embodiment, the second compound may include a compound represented by Formula 2:




embedded image - Formula 2


wherein, in Formula 2,

  • L61 to L63 may each independently be a single bond, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,
  • b61 to b63 may each independently be an integer from 1 to 5,
  • X64 may be N or C(R64), X65 may be N or C(R65), X66 may be N or C(R66), and at least one of X64 to X66 may be N,
  • R61 to R66 may respectively be the same as those described in the present specification, and
  • R10a may be the same as described in the present specification.


In an embodiment, the third compound may include a compound represented by Formula 3-1, a compound represented by Formula 3-2, a compound represented by Formula 3-3, a compound represented by Formula 3-4, a compound represented by Formula 3-5, or any combination thereof:




embedded image - Formula 3-1




embedded image - Formula 3-2




embedded image - Formula 3-3




embedded image - Formula 3-4




embedded image - Formula 3-5




  • wherein, in Formulae 3-1 to 3-5,

  • ring CY71 to ring CY74 may each independently be a TT electron-rich C3-C60 cyclic group or a pyridine group,

  • X82 may be a single bond, O, S, N-[(L82)b82-R82], C(R82a)(R82b), or Si(R82a)(R82b),

  • X83 may be a single bond, O, S, N-[(L33)b33-R33], C(R83a)(R83b), or Si(R83a)(R83b),

  • X84 may be O, S, N-[(L84)b84-R84], C(R84a)(R84b), or Si(Rs4a)(Rs4b),

  • X85 may be C or Si,

  • L81 to L85 may each independently be a single bond, *—C(Q4)(Q5)—*’, *—Si(Q4)(Q5)—*’, a TT electron-rich C3-C60 cyclic group unsubstituted or substituted with at least one R10a, or a pyridine group unsubstituted or substituted with at least one R10a, wherein Q4 and Q5 may each be understood by referring to the description of Q1 provided herein,

  • b81 to b85 may each independently be an integer from 1 to 5,

  • R71 to R74, R81 to R85, R82a, R82b, R83a, R83b, R84a, and R84b may respectively be the same as those described in the present specification,

  • a71 to a74 may each independently be an integer from 0 to 20, and

  • R10a may be the same as described in the present specification.



In an embodiment, the fourth compound may be a compound represented by Formula 502, a compound represented by Formula 503, or any combination thereof:




embedded image - Formula 502




embedded image - Formula 503


wherein, in Formulae 502 and 503,

  • ring A501 to ring A504 may each independently be a C3-C60 carbocyclic group or a C1-C60 heterocyclic group,
  • Y505 may be O, S, N(R505), B(R505), C(R505a)(R505b), or Si(R505a)(R505b),
  • Y506 may be O, S, N(R506), B(R506), C(R506a)(R506b), or Si(R506a)(R506b),
  • Y507 may be O, S, N(R507), B(R507), C(R507a)(R507b), or Si(R507a)(R507b),
  • Y508 may be O, S, N(R508), B(R508), C(R508a)(R508b), or Si(R508a)(R508b),
  • Y51 and Y52 may each independently be B, P(═O), or S(═O),
  • R500a, R500b, R501 to R508, R505a, R505b, R506a, R506b, R507a, R507b, R508a, and R508b are respectively the same as those described in the present specification,
  • a501 to a504 may each independently be an integer from 0 to 20, and
  • R10a may be the same as described in the present specification.


Description of Formulae 2 to 4


b
61 to b63 in Formula 2 may respectively indicate the numbers of L61(s) to L63(S), and b61 to b63 may each be an integer from 1 to 5. When b61 is 2 or greater, at least two L61 (s) may be identical to or different from each other, when b62 is 2 or greater, at least two L62(S) may be identical to or different from each other, and when b63 is 2 or greater, at least two L63(S) may be identical to or different from each other. In an embodiment, b61 to b63 may each independently be 1 or 2.


L61 to L63 in Formula 2 may each independently be:

  • a single bond; or
  • a benzene group, a naphthalene group, an anthracene group, a phenanthrene group, a triphenylene group, a pyrene group, a chrysene group, a cyclopentadiene group, a furan group, a thiophene group, a silole group, an indene group, a fluorene group, an indole group, a carbazole group, a benzofuran group, a dibenzofuran group, a benzothiophene group, a dibenzothiophene group, a benzosilole group, a dibenzosilole group, an azafluorene group, an azacarbazole group, an azadibenzofuran group, an azadibenzothiophene group, an azadibenzosilole group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a phenanthroline group, a pyrrole group, a pyrazole group, an imidazole group, a triazole group, an oxazole group, an isooxazole group, a thiazole group, an isothiazole group, an oxadiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a benzoxazole group, a benzothiazole group, a benzoxadiazole group, a benzothiadiazole group, a dibenzooxacilline group, a dibenzothiacilline group, a dibenzodihydroazacilline group, a dibenzodihydrodicilline group, a dibenzodihydrocilline group, a dibenzodioxane group, a dibenzooxathiene group, a dibenzooxazine group, a dibenzopyran group, a dibenzodithiine group, a dibenzothiazine group, a dibenzothiopyran group, a dibenzocyclohexadiene group, a dibenzodihydropyridine group, or a dibenzodihydropyrazine group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a triazinyl group, a fluorenyl group, a dimethylfluorenyl group, a diphenylfluorenyl group, a carbazolyl group, a phenylcarbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a dibenzosilolyl group, a dimethyldibenzosilolyl group, a diphenyldibenzosilolyl group, —O(Q31), —S(Q31), —Si(Q31)(Q32)(Q33), —N(Q31)(Q32), —B(Q31)(Q32), —P(Q31)(Q32), —C(═O)(Q31), —S(═O)2(Q31), —P(═O)(Q31)(Q32), or any combination thereof,
  • wherein Q31 to Q33 may each independently be hydrogen, deuterium, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, a pyridinyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazinyl group, or a triazinyl group.


In an embodiment, in Formula 2, a bond between L51 and R51, a bond between L52 and R52, a bond between L53 and R53, a bond between at least two L51(s), a bond between at least two L52(s), a bond between at least two L53(s), a bond between L51 and a carbon atom between X54 and X55 in Formula 2, a bond between L52 and a carbon atom between X54 and X56 in Formula 2, and a bond between L53 and a carbon atom between X55 and X56 in Formula 2 may each be a “carbon-carbon single bond”.


In Formula 2, X64 may be N or C(R64), X65 may be N or C(R65), X66 may be N or C(R66), at least one of X64 to X66 may be N. R64 to R66 may respectively be the same as those described in the present specification. In an embodiment, two or three of X64 to X66 may each be N.


R61 to R66, R71 to R74, R81 to R85, R82a, R82b, R83a, R83b, R84a and R84b, R500a, R500b, R501 to R508, R505a, R505b, R506a, R506b, R507a, R507b, R508a, and R508b may each independently be hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C60 alkyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkenyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkynyl group unsubstituted or substituted with at least one R10a, a C1-C60 alkoxy group unsubstituted or substituted with at least one R10a, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, a C6-C60 aryloxy group unsubstituted or substituted with at least one R10a, a C6-C60 arylthio group unsubstituted or substituted with at least one R10a, —C(Q1)(Q2)(Q3), —Si(Q1)(Q2)(Q3), —N(Q1)(Q2), —B(Q1)(Q2), —C(═O)(Q1), —S(═O)2(Q1), or —P(═O)(Q1)(Q2). Q1 to Q3 are respectively the same as those described in the present specification.


In an embodiment, i) R1 to R5, Z11, Z12, Z21, and Z22 in Formula 1, ii) R11, R12, R21, R22, R31 to R34, R41 to R45, R5a, R5b, R51, and R52 in Formulae A1(1) to A1 (32), A1-1 to A1-4, A2-1 to A2-8, A3-1 to A3-15, A4-1 to A4-32, CY1(a), CY1-1, and CY1-2, iii) R51 to R56, R71 to R74, R81 to R85, R82a, R82b, R83a, R83b, R84a and R84b, R500a, R500b, R501 to R508, R505a, R505b, R506a, R506b, R507a, R507b, R508a, and R508b in Formulae 2, 3-1 to 3-5, 502, and 503, and iv) R10a may each independently be:

  • hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C20 alkyl group, or a C1-C20 alkoxy group;
  • a C1-C20 alkyl group or a C1-C20 alkoxy group, each substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, a C1-C10 alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, or any combination thereof;
  • a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a C1-C10 alkylphenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an azacarbazolyl group, an azadibenzofuranyl group, an azadibenzothiophenyl group, an azafluorenyl group, an azadibenzosilolyl group, or a group represented by Formula 91, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, a C1-C20 alkyl group, a C1-C20 alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a C1-C10 alkylphenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, —O(Q31), —S(Q31), —Si(Q31)(Q32)(Q33), —N(Q31)(Q32), —B(Q31)(Q32), —P(Q31)(Q32), —C(═O)(Q31), —S(═O)2(Q31), —P(═O)(Q31)(Q32), or any combination thereof; or
  • —C(Q1)(Q2)(Q3), —Si(Q1)(Q2)(Q3), —N(Q1)(Q2), —B(Q1)(Q2), —C(═O)(Q1), —S(═O)2(Q1), or —P(═O)(Q1)(Q2), and
  • Q1 to Q3 and Q31 to Q33 may each independently be:
    • —CH3, —CD3, —CD2H, —CDH2, —CH2CH3, —CH2CD3, —CH2CD2H, —CH2CDH2, —CHDCH3, —CHDCD2H, —CHDCDH2, —CHDCD3, —CD2CD3, —CD2CD2H, or —CD2CDH2; or
  • an n-propyl group, an iso-propyl group, an n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazinyl group, or a triazinyl group, each unsubstituted or substituted with deuterium, a C1-C10 alkyl group, a phenyl group, a biphenyl group, a pyridinyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazinyl group, a triazinyl group, or any combination thereof:
  • embedded image - Formula 91
  • wherein, in Formula 91,
  • ring CY91 and ring CY92 may each independently be a C5-C30 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C30 heterocyclic group unsubstituted or substituted with at least one R10a,
  • X91 may be a single bond, O, S, N(R91), B(R91), C(R91a)(R91b), or Si(R91a)(R91b),
  • R91, R91a, and R91b may respectively be understood by referring to the descriptions of R82, R82a, and R82b provided herein,
  • R10a may be the same as described in the present specification, and
  • * indicates a binding site to an adjacent atom.


In an embodiment, in Formula 91,

  • ring CY91 and ring CY92 may each independently be a benzene group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, or a triazine group, each unsubstituted or substituted with at least one R10a, and
  • R91, R91a, and R91b may each independently be selected from:
  • hydrogen or a C1-C10 alkyl group; or
  • a phenyl group, a pyridinyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazinyl group, or a triazinyl group, each unsubstituted or substituted with deuterium, a C1-C10 alkyl group, a phenyl group, a biphenyl group, a pyridinyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazinyl group, a triazinyl group, or any combination thereof.


In an embodiment, i) R1 to R5, Z11, Z12, Z21, and Z22 in Formula 1, ii) R11, R12, R21, R22, R31 to R34, R41 to R45, R5a, R5b, R51, and R52 in Formulae A1(1) to A1 (32), A1-1 to A1-4, A2-1 to A2-8, A3-1 to A3-15, A4-1 to A4-32, CY1(a), CY1-1, and CY1-2, iii) R51 to R56, R71 to R74, R81 to R85, R82a, R82b, R83a, R83b, R84a and R84b, R500a, R500b, R501 to R508, R505a, R505b, R506a, R506b, R507a, R507b, R508a, and R508b in Formulae 2, 3-1 to 3-5, 502, and 503, and iv) R10a may each independently be:

  • hydrogen, deuterium, —F, a cyano group, a nitro group, —CH3, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, groups represented by one of Formulae 9-1 to 9-19, groups represented by one of Formulae 10-1 to 10-246, —C(Q1)(Q2)(Q3), —Si(Q1)(Q2)(Q3), or —P(═O)(Q1)(Q2), wherein Q1 to Q3 may respectively be understood by referring to the descriptions of Q1 to Q3 provided herein:
  • embedded image - 9-1
  • embedded image - 9-2
  • embedded image - 9-3
  • embedded image - 9-4
  • embedded image - 9-5
  • embedded image - 9-6
  • embedded image - 9-7
  • embedded image - 9-8
  • embedded image - 9-9
  • embedded image - 9-10
  • embedded image - 9-11
  • embedded image - 9-12
  • embedded image - 9-13
  • embedded image - 9-14
  • embedded image - 9-15
  • embedded image - 9-16
  • embedded image - 9-17
  • embedded image - 9-16
  • embedded image - 9-19
  • embedded image - 10-1
  • embedded image - 10-2
  • embedded image - 10-3
  • embedded image - 10-4
  • embedded image - 10-5
  • embedded image - 10-6
  • embedded image - 10-7
  • embedded image - 10-8
  • embedded image - 10-9
  • embedded image - 10-10
  • embedded image - 10-11
  • embedded image - 10-12
  • embedded image - 10-13
  • embedded image - 10-14
  • embedded image - 10-15
  • embedded image - 10-16
  • embedded image - 10-17
  • embedded image - 10-18
  • embedded image - 10-19
  • embedded image - 10-20
  • embedded image - 10-21
  • embedded image - 10-22
  • embedded image - 10-23
  • embedded image - 10-24
  • embedded image - 10-25
  • embedded image - 10-26
  • embedded image - 10-27
  • embedded image - 10-28
  • embedded image - 10-29
  • embedded image - 10-30
  • embedded image - 10-31
  • embedded image - 10-32
  • embedded image - 10-33
  • embedded image - 10-34
  • embedded image - 10-35
  • embedded image - 10-36
  • embedded image - 10-37
  • embedded image - 10-38
  • embedded image - 10-39
  • embedded image - 10-40
  • embedded image - 10-41
  • embedded image - 10-42
  • embedded image - 10-43
  • embedded image - 10-44
  • embedded image - 10-45
  • embedded image - 10-46
  • embedded image - 10-47
  • embedded image - 10-46
  • embedded image - 10-49
  • embedded image - 10-50
  • embedded image - 10-51
  • embedded image - 10-52
  • embedded image - 10-53
  • embedded image - 10-54
  • embedded image - 10-55
  • embedded image - 10-56
  • embedded image - 10-57
  • embedded image - 10-58
  • embedded image - 10-59
  • embedded image - 10-60
  • embedded image - 10-61
  • embedded image - 10-62
  • embedded image - 10-63
  • embedded image - 10-64
  • embedded image - 10-65
  • embedded image - 10-66
  • embedded image - 10-67
  • embedded image - 10-68
  • embedded image - 10-69
  • embedded image - 10-70
  • embedded image - 10-71
  • embedded image - 10-72
  • embedded image - 10-73
  • embedded image - 10-74
  • embedded image - 10-75
  • embedded image - 10-76
  • embedded image - 10-77
  • embedded image - 10-78
  • embedded image - 10-79
  • embedded image - 10-80
  • embedded image - 10-81
  • embedded image - 10-82
  • embedded image - 10-83
  • embedded image - 10-84
  • embedded image - 10-85
  • embedded image - 10-86
  • embedded image - 10-87
  • embedded image - 10-88
  • embedded image - 10-89
  • embedded image - 10-90
  • embedded image - 10-91
  • embedded image - 10-92
  • embedded image - 10-93
  • embedded image - 10-94
  • embedded image - 10-95
  • embedded image - 10-96
  • embedded image - 10-97
  • embedded image - 10-98
  • embedded image - 10-99
  • embedded image - 10-100
  • embedded image - 10-101
  • embedded image - 10-102
  • embedded image - 10-103
  • embedded image - 10-104
  • embedded image - 10-105
  • embedded image - 10-106
  • embedded image - 10-107
  • embedded image - 10-108
  • embedded image - 10-109
  • embedded image - 10-110
  • embedded image - 10-111
  • embedded image - 10-112
  • embedded image - 10-113
  • embedded image - 10-114
  • embedded image - 10-115
  • embedded image - 10-116
  • embedded image - 10-117 10-118
  • embedded image - 10-119
  • embedded image - 10-120
  • embedded image - 10-121
  • embedded image - 10-122
  • embedded image - 10-123
  • embedded image - 10-124
  • embedded image - 10-125 10-126
  • embedded image - 10-127
  • embedded image - 10-128
  • embedded image - 10-129
  • embedded image - 10-130
  • embedded image - 10-131
  • embedded image - 10-132
  • embedded image - 10-133
  • embedded image - 10-134
  • embedded image - 10-135 10-136
  • embedded image - 10-137
  • embedded image - 10-138
  • embedded image - 10-139
  • embedded image - 10-140
  • embedded image - 10-141
  • embedded image - 10-142
  • embedded image - 10-143
  • embedded image - 10-144
  • embedded image - 10-145
  • embedded image - 10-146
  • embedded image - 10-147
  • embedded image - 10-148
  • embedded image - 10-149
  • embedded image - 10-150
  • embedded image - 10-151
  • embedded image - 10-152
  • embedded image - 10-153
  • embedded image - 10-154
  • embedded image - 10-155
  • embedded image - 10-156
  • embedded image - 10-157
  • embedded image - 10-158
  • embedded image - 10-159
  • embedded image - 10-160
  • embedded image - 10-161
  • embedded image - 10-162
  • embedded image - 10-163
  • embedded image - 10-164
  • embedded image - 10-165
  • embedded image - 10-166 10-167
  • embedded image - 10-168
  • embedded image - 10-169
  • embedded image - 10-170
  • embedded image - 10-171
  • embedded image - 10-172
  • embedded image - 10-173
  • embedded image - 10-174
  • embedded image - 10-175
  • embedded image - 10-176
  • embedded image - 10-177
  • embedded image - 10-178
  • embedded image - 10-179
  • embedded image - 10-180
  • embedded image - 10-181
  • embedded image - 10-182
  • embedded image - 10-183
  • embedded image - 10-184
  • embedded image - 10-185
  • embedded image - 10-186
  • embedded image - 10-187
  • embedded image - 10-188
  • embedded image - 10-189
  • embedded image - 10-190
  • embedded image - 10-191
  • embedded image - 10-192
  • embedded image - 10-193
  • embedded image - 10-194
  • embedded image - 10-195
  • embedded image - 10-196
  • embedded image - 10-197
  • embedded image - 10-198
  • embedded image - 10-199
  • embedded image - 10-200
  • embedded image - 10-201
  • embedded image - 10-202
  • embedded image - 10-203
  • embedded image - 10-204 10-205 10-206
  • embedded image - 10-207
  • embedded image - 10-208
  • embedded image - 10-209
  • embedded image - 10-210
  • embedded image - 10-211
  • embedded image - 10-212
  • embedded image - 10-213
  • embedded image - 10-214
  • embedded image - 10-215
  • embedded image - 10-216
  • embedded image - 10-217
  • embedded image - 10-218
  • embedded image - 10-219
  • embedded image - 10-220
  • embedded image - 10-221
  • embedded image - 10-222
  • embedded image - 10-223
  • embedded image - 10-224
  • embedded image - 10-225
  • embedded image - 10-226
  • embedded image - 10-227
  • embedded image - 10-228
  • embedded image - 10-229
  • embedded image - 10-230
  • embedded image - 10-231
  • embedded image - 10-232
  • embedded image - 10-233
  • embedded image - 10-234
  • embedded image - 10-235
  • embedded image - 10-236
  • embedded image - 10-237
  • embedded image - 10-238
  • embedded image - 10-239
  • embedded image - 10-240
  • embedded image - 10-241
  • embedded image - 10-242
  • embedded image - 10-243
  • embedded image - 10-244
  • embedded image - 10-245
  • embedded image - 10-246
  • wherein, in Formulae 9-1 to 9-19 and 10-1 to 10-246, * indicates a binding site to an adjacent atom, “Ph” represents a phenyl group, and “TMS” represents a trimethylsilyl group.


In Formulae 3-1 to 3-5, 502, and 503, a71 to a74 and a501 to a504 may respectively indicate the number of R71(s) to R74(s) and R501(s) to R504(s), and a71 to a74 and a501 to a504 may each independently be an integer from 0 to 20. When a71 is 2 or greater, at least two R71(s) may be identical to or different from each other, when a72 is 2 or greater, at least two R72(s) may be identical to or different from each other, when a73 is 2 or greater, at least two R73(s) may be identical to or different from each other, when a74 is 2 or greater, may be identical to or different from each other R74(s) may be identical to or different from each other, when a501 is 2 or greater, at least two R501(s) may be identical to or different from each other, when a502 is 2 or greater, at least two R502(s) may be identical to or different from each other, when a503 is 2 or greater, at least two R503(s) may be identical to or different from each other, and when a504 is 2 or greater, at least two R504(s) may be identical to or different from each other. a71 to a74 and a501 to a504 may each independently be an integer from 0 to 8.


In some embodiments, in Formula 2, the group represented by *-(L61)b61-R61 and the group represented by *-(L62)b62-R62 may not be a phenyl group.


In some embodiments, in Formula 2, the group represented by *-(L61)b61-R61 may be identical to the group represented by *-(L62)b62-R62.


In one or more embodiments, in Formula 2, the group represented by *-(L61)b61-R61 and the group represented by *-(L62)b62-R62 may be different from each other.


In one or more embodiments, in Formula 2, b61 and b62 may each be 1, 2, or 3, L61 and L62 may each independently be a benzene group, a pyridine group, a pyrimidine group, a pyridazine group, a pyrazine group, or a triazine group unsubstituted or substituted with at least one R10a.


In some embodiments, in Formula 2, R61 and R62 may each independently be a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, a C6-C60 aryloxy group unsubstituted or substituted with at least one R10a, a C6-C60 arylthio group unsubstituted or substituted with at least one R10a, —C(Q1)(Q2)(Q3), or —Si(Q1)(Q2)(Q3),


wherein Q1 to Q3 may each independently be a C3-C60 carbocyclic group or a C1-C60 heterocyclic group, each unsubstituted or substituted with deuterium, —F, a cyano group, a C1-C60 alkyl group, a C1-C60 alkoxy group, a phenyl group, a biphenyl group, or any combination thereof.


In an embodiment,

  • in Formula 2, the group represented by *-(Le1)b61-R61 may be a group represented by one of Formulae CY51-1 to CY51-26,
  • in Formula 2, the group represented by *-(L62)b62-R62 may be a group represented by one of Formulae CY52-1 to CY52-26, and/or
  • in Formula 2, the group represented by *-(L63)b63-R63 may be a group represented by one of Formulae CY53-1 to CY53-27, —C(Q1)(Q2)(Q3), or —Si(Q1)(Q2)(Q3)—
  • embedded image - CY51-1
  • embedded image - CY51-2
  • embedded image - CY51-3
  • embedded image - CY51-4
  • embedded image - CY51-5
  • embedded image - CY51-6
  • embedded image - CY51-7
  • embedded image - CY51-8
  • embedded image - CY51-9
  • embedded image - CY51-10
  • embedded image - CY51-11
  • embedded image - CY51-12
  • embedded image - CY51-13
  • embedded image - CY51-14
  • embedded image - CY51-15
  • embedded image - CY51-16
  • embedded image - CY51-17
  • embedded image - CY51-18
  • embedded image - CY51-19
  • embedded image - CY51-20
  • embedded image - CY51-21
  • embedded image - CY51-22
  • embedded image - CY51-23
  • embedded image - CY51-24
  • embedded image - CY51-25
  • embedded image - CY51-26
  • embedded image - CY52-1
  • embedded image - CY52-2
  • embedded image - CY52-3
  • embedded image - CY52-4
  • embedded image - CY52-5
  • embedded image - CY52-6
  • embedded image - CY52-7
  • embedded image - CY52-8
  • embedded image - CY52-9
  • embedded image - CY52-10
  • embedded image - CY52-11
  • embedded image - CY52-12
  • embedded image - CY52-13
  • embedded image - CY52-14
  • embedded image - CY52-15
  • embedded image - CY52-16 CY52-17
  • embedded image - CY62-18
  • embedded image - CY52-19
  • embedded image - CY52-20
  • embedded image - CY52-21
  • embedded image - CY52-22
  • embedded image - CY52-23
  • embedded image - CY52-24
  • embedded image - CY52-25
  • embedded image - CY52-26
  • embedded image - CY53-1
  • embedded image - CY53-2
  • embedded image - CY53-3
  • embedded image - CY53-4
  • embedded image - CY53-5
  • embedded image - CY53-6
  • embedded image - CY53-7
  • embedded image - CY53-8
  • embedded image - CY53-9
  • embedded image - CY53-10
  • embedded image - CY53-11
  • embedded image - CY53-12
  • embedded image - CY53-13
  • embedded image - CY53-14
  • embedded image - CY53-15
  • embedded image - CY63-16
  • embedded image - CY53-17
  • embedded image - CY53-18
  • embedded image - CY53-19
  • embedded image - CY53-20
  • embedded image - CY53-21
  • embedded image - CY53-22
  • embedded image - CY53-23
  • embedded image - CY53-24
  • embedded image - CY53-25
  • embedded image - CY53-26
  • embedded image - CY53-27
  • wherein, in Formulae CY51-1 to CY51-26, CY52-1 to CY52-26, and CY53-1 to CY53-27,
  • Y63 may be a single bond, O, S, N(R63), B(R63), C(R63a)(R63b), or Si(R63a)(R63b),
  • Y64 may be a single bond, O, S, N(R64), B(R64), C(R64a)(R64b), or Si(R64a)(R64b),
  • Y67 may be a single bond, O, S, N(R67), B(R67), C(R67a)(R67b), or Si(R67a)(R67b),
  • Y68 may be a single bond, O, S, N(R68), B(R68), C(R68a)(R68b), or Si(R68a)(R68b),
  • each of Y63 and Y64 in Formulae CY51-16 and CY51-17 may not be a single bond,
  • each of Y67 and Y68 in Formulae CY52-16 and CY52-17 may not be a single bond,
  • R51a to R51e, R61 to R64, R63a, R63b, R64a, and R64b may each be understood by referring to the description of R51, and R51a to R51e may not each be hydrogen,
  • R52a to R52e, R65 to R68, R67a, R67b, R68a, and R68b may each be understood by referring to the description of R52, and R52a to R52e may not each be hydrogen,
  • R53a to R53e, R69a, and R69b may each be understood by referring to the description of R53, and R53a to R53e may not each be hydrogen, and
  • * indicates a binding site to an adjacent atom.


In an embodiment,


R51a to R51e and R52a to R52e in Formulae CY51-1 to CY51-26 and Formulae CY52-1 to 52-26 may each independently be:

  • a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a C1-C10 alkylphenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an azacarbazolyl group, an azadibenzofuranyl group, an azadibenzothiophenyl group, an azafluorenyl group, an azadibenzosilolyl group, or a group represented by Formula 91, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, —CD3, —CD2H, —CDH2, —CF3, —CF2H, —CFH2, a hydroxyl group, a cyano group, a nitro group, a C1-C20 alkyl group, a C1-C20 alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a biphenyl group, a C1-C10 alkylphenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, or any combination thereof; or
  • —C(Q1)(Q2)(Q3) or —Si(Q1)(Q2)(Q3),
  • wherein Q1 to Q3 may each independently be a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazinyl group, or a triazinyl group, each unsubstituted or substituted with deuterium, a C1-C10 alkyl group, a phenyl group, a biphenyl group, a pyridinyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazinyl group, a triazinyl group, or any combination thereof,
  • in Formulae CY51-16 and CY51-17, i) Y63 may be O or S and Y64 may be Si(R64a)(R64b), or ii) Y63 may be Si(R63a)(R63b) and Y64 may be O or S, and
  • in Formulae CY52-16 and CY52-17, i) Y67 may be O or S, and Y68 may be Si(R68a)(R68b), or ii) Y67 may be Si(R67a)(R67b), and Y68 may be O or S.


In an embodiment, L81 to L85 in Formulae 3-1 to 3-5 may each independently be:

  • a single bond; or
  • *—C(Q4)(Q5)—*’ or *—Si(Q4)(Q5)—*’; or a benzene group, a naphthalene group, an anthracene group, a phenanthrene group, a triphenylene group, a pyrene group, a chrysene group, a cyclopentadiene group, a furan group, a thiophene group, a silole group, an indene group, a fluorene group, an indole group, a carbazole group, a benzofuran group, a dibenzofuran group, a benzothiophene group, a dibenzothiophene group, a benzosilole group, a dibenzosilole group, an azafluorene group, an azacarbazole group, an azadibenzofuran group, an azadibenzothiophene group, an azadibenzosilole group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a phenanthroline group, a pyrrole group, a pyrazole group, an imidazole group, a triazole group, an oxazole group, an isooxazole group, a thiazole group, an isothiazole group, an oxadiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a benzoxazole group, a benzothiazole group, a benzoxadiazole group, or a benzothiadiazole group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a triazinyl group, a fluorenyl group, a dimethylfluorenyl group, a diphenylfluorenyl group, a carbazolyl group, a phenylcarbazolyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a dibenzosilolyl group, a dimethyldibenzosilolyl group, a diphenyldibenzosilolyl group, —O(Q31), —S(Q31), —Si(Q31)(Q32)(Q33), —N(Q31)(Q32), —B(Q31)(Q32), —P(Q31)(Q32), —C(═O)(Q31), —S(═O)2(Q31), —P(═O)(Q31)(Q32), or any combination thereof,
  • wherein Q4, Q5, and Q31 to Q33 may each independently be hydrogen, deuterium, a C1-C20 alkyl group, a C1-C20 alkoxy group, a phenyl group, a biphenyl group, a terphenyl group, a pyridinyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazinyl group, or a triazinyl group.


In some embodiments, a group represented by




embedded image


in Formulae 3-1 and 3-2 may be represented by one of Formulae CY71-1(1) to CY71-1(8),

  • a group represented by
  • embedded image
  • in Formulae 3-1 and 3-3 may be represented by one of Formulae CY71-2(1) to CY71-2(8),
  • a group represented by
  • embedded image
  • in Formulae 3-2 and 3-4 may be represented by one of Formulae CY71-3(1) to CY71-3(32),
  • a group represented by
  • embedded image
  • in Formulae 3-3 to 3-5 may be represented by one of Formulae CY71-4(1) to CY71-4(32), and/or
  • a group represented by
  • embedded image
  • in Formula 3-5 may be represented by one of Formulae CY71-5(1) to CY71-5(8):
  • embedded image - CY71-1(1)
  • embedded image - CY71-1(2)
  • embedded image - CY71-1(3)
  • embedded image - CY71-1(4)
  • embedded image - CY71-1(5)
  • embedded image - CY71-1(6)
  • embedded image - CY71-1(7)
  • embedded image - CY71-1(8)
  • embedded image - CY71-2(1)
  • embedded image - CY71-2(2)
  • embedded image - CY71-2(3)
  • embedded image - CY71-2(4)
  • embedded image - CY71-2(5)
  • embedded image - CY71-2(6)
  • embedded image - CY71-2(7)
  • embedded image - CY71-2(8)
  • embedded image - CY71-3(1)
  • embedded image - CY71-3(2)
  • embedded image - CY71-3(3)
  • embedded image - CY71-3(4)
  • embedded image - CY71-3(5)
  • embedded image - CY71-3(6)
  • embedded image - CY71-3(7)
  • embedded image - CY71-3(8)
  • embedded image - CY71-3(9)
  • embedded image - CY71-3(10)
  • embedded image - CY71-3(11)
  • embedded image - CY71-3(12)
  • embedded image - CY71-3(13)
  • embedded image - CY71-3(14)
  • embedded image - CY71-3(15)
  • embedded image - CY71-3(16)
  • embedded image - CY71-3(17)
  • embedded image - CY71-3(18)
  • embedded image - CY71-3(19)
  • embedded image - CY71-3(20)
  • embedded image - CY71-3(21)
  • embedded image - CY71-3(22)
  • embedded image - CY71-3(23)
  • embedded image - CY71-3(24)
  • embedded image - CY71-3(25)
  • embedded image - CY71-3(26)
  • embedded image - CY71-3(27)
  • embedded image - CY71-3(28)
  • embedded image - CY71-3(29)
  • embedded image - CY71-3(30)
  • embedded image - CY71-3(31)
  • embedded image - CY71-3(32)
  • embedded image - CY71-4(1)
  • embedded image - CY71-4(2)
  • embedded image - CY71-4(3)
  • embedded image - CY71-4(4)
  • embedded image - CY71-4(5)
  • embedded image - CY71-4(6)
  • embedded image - CY71-4(7)
  • embedded image - CY71-4(8)
  • embedded image - CY71-4(9)
  • embedded image - CY71-4(10)
  • embedded image - CY71-4(11)
  • embedded image - CY71-4(12)
  • embedded image - CY71-4(13)
  • embedded image - CY71-4(14)
  • embedded image - CY71-4(15)
  • embedded image - CY71-4(16)
  • embedded image - CY71-4(17)
  • embedded image - CY71-4(18)
  • embedded image - CY71-4(19)
  • embedded image - CY71-4(20)
  • embedded image - CY71-4(21)
  • embedded image - CY71-4(22)
  • embedded image - CY71-4(23)
  • embedded image - CY71-4(24)
  • embedded image - CY71-4(25)
  • embedded image - CY71-4(26)
  • embedded image - CY71-4(27)
  • embedded image - CY71-4(28)
  • embedded image - CY71-4(29)
  • embedded image - CY71-4(30)
  • embedded image - CY71-4(31)
  • embedded image - CY71-4(32)
  • embedded image - CY71-5(1)
  • embedded image - CY71-5(2)
  • embedded image - CY71-5(3)
  • embedded image - CY71-5(4)
  • embedded image - CY71-5(5)
  • embedded image - CY71-6(6)
  • embedded image - CY71-5(7)
  • embedded image - CY71-5(8)
  • wherein, in Formulae CY71-1(1) to CY71-1(8), CY71-2(1) to CY71-2(8), CY71-3(1) to CY71-3(32), CY71-4(1) to CY71-4(32), and CY71-5(1) to CY71-5(8),
  • X81 to X85, L81, b81, R81, and R85 may respectively be the same as those described in the present specification,
  • X86 may be a single bond, O, S, N(R86), B(R86), C(R86a)(R86b), or Si(R86a)(R86b),
  • X87 may be a single bond, O, S, N(R87), B(R87), C(R87a)(R87b), or Si(R87a)(R87b),
  • in Formulae CY71-1(1) to CY71-1(8) and CY71-4(1) to CY71-4(32), X86 and X87 may not be a single bond at the same time,
  • X88 may be a single bond, O, S, N(R88), B(R88), C(R88a)(R88b), or Si(R88a)(R88b),
  • X89 may be a single bond, O, S, N(R89), B(R89), C(R89a)(R89b), or Si(R89a)(R89b),
  • in Formulae CY71-2(1) to CY71-2(8), CY71-3(1) to CY71-3(32), and CY71-5(1) to CY71-5(8), X88 and X89 may not be a single bond at the same time, and
  • R86 to R89, R86a, R86b, R87a, R87b, R88a, R88b, R89a, and R89b may each be understood by referring to the description of R81 provided herein.


Examples of the Second Compound, the Third Compound, and the Fourth Compound

In one or more embodiments, the second compound may include at least one of Compounds ETH1 to ETH84:




embedded image - ETH1




embedded image - ETH2




embedded image - ETH3




embedded image - ETH4




embedded image - ETH5




embedded image - ETH6




embedded image - ETH7




embedded image - ETH8




embedded image - ETH9




embedded image - ETH10




embedded image - ETH11




embedded image - ETH12




embedded image - ETH13




embedded image - ETH14




embedded image - ETH15




embedded image - ETH16




embedded image - ETH17




embedded image - ETH18




embedded image - ETH19




embedded image - ETH20




embedded image - ETH21




embedded image - ETH22




embedded image - ETH23




embedded image - ETH24




embedded image - ETH25




embedded image - ETH26




embedded image - ETH27




embedded image - ETH28




embedded image - ETH29




embedded image - ETH30




embedded image - ETH31




embedded image - ETH32




embedded image - ETH33




embedded image - ETH34




embedded image - ETH35




embedded image - ETH36




embedded image - ETH37




embedded image - ETH38




embedded image - ETH39




embedded image - ETH40




embedded image - ETH41




embedded image - ETH42




embedded image - ETH43




embedded image - ETH44




embedded image - ETH45




embedded image - ETH46




embedded image - ETH47




embedded image - ETH48




embedded image - ETH49




embedded image - ETH50




embedded image - ETH51




embedded image - ETH52




embedded image - ETH53




embedded image - ETH54




embedded image - ETH55




embedded image - ETH56




embedded image - ETH57




embedded image - ETH58




embedded image - ETH59




embedded image - ETH60




embedded image - ETH61




embedded image - ETH62




embedded image - ETH63




embedded image - ETH64




embedded image - ETH65




embedded image - ETH86




embedded image - ETH67




embedded image - ETH88




embedded image - ETH69




embedded image - ETH70




embedded image - ETH71




embedded image - ETH72




embedded image - ETH73




embedded image - ETH74




embedded image - ETH75




embedded image - ETH76




embedded image - ETH77




embedded image - ETH78




embedded image - ETH79




embedded image - ETH80




embedded image - ETH81




embedded image - ETH82




embedded image - ETH83




embedded image - ETH84


In an embodiment, the third compound may include at least one of Compounds HTH1 to HTH52:




embedded image - HTH1




embedded image - HTH2




embedded image - HTH3




embedded image - HTH4




embedded image - HTH5




embedded image - HTH6




embedded image - HTH7




embedded image - HTH8




embedded image - HTH9




embedded image - HTH10




embedded image - HTH11




embedded image - HTH12




embedded image - HTH13




embedded image - HTH14




embedded image - HTH15




embedded image - HTH16




embedded image - HTH17




embedded image - HTH18




embedded image - HTH19




embedded image - HTH20




embedded image - HTH21




embedded image - HTH22




embedded image - HTH23




embedded image - HTH24




embedded image - HTH25




embedded image - HTH26




embedded image - HTH27




embedded image - HTH28




embedded image - HTH29




embedded image - HTH30




embedded image - HTH31




embedded image - HTH32




embedded image - HTH33




embedded image - HTH34




embedded image - HTH35




embedded image - HTH36




embedded image - HTH37




embedded image - HTH38




embedded image - HTH39




embedded image - HTH40




embedded image - HTH41




embedded image - HTH42




embedded image - HTH43




embedded image - HTH44




embedded image - HTH45




embedded image - HTH46




embedded image - HTH47




embedded image - HTH48




embedded image - HTH49




embedded image - HTH50




embedded image - HTH51




embedded image - HTHS2


In an embodiment, the fourth compound may include at least one of Compounds DFD1 to DFD12:




embedded image - DFD1




embedded image - DFD2




embedded image - DFD3




embedded image - DFD4




embedded image - DFD5




embedded image - DFD6




embedded image - DFD7




embedded image - DFD8




embedded image - DFD9




embedded image - DFD10




embedded image - DFD11




embedded image - DFD12


In the above Compounds, “Ph” represents a phenyl group, “D5” represents substitution with five deuterium atoms (e.g., five hydrogen atoms are replaced with five deuterium atoms), and “D4” represents substitution with four deuterium atoms (e.g., four hydrogen atoms are replaced with four deuterium atoms). For example, a group represented by




embedded image


may be identical to a group represented by




embedded image


In some embodiments, the light-emitting device may satisfy at least one of Conditions 1 to 4:

  • Condition 1
    • LUMO energy level (eV) of the third compound > LUMO energy level (eV) of the first compound
  • Condition 2
    • LUMO energy level (eV) of the first compound > LUMO energy level (eV) of the second compound
  • Condition 3
    • HOMO energy level (eV) of the first compound > HOMO energy level (eV) of the third compound
  • Condition 4
    • HOMO energy level (eV) of the third compound > HOMO energy level (eV) of the second compound


The highest occupied molecular orbital (HOMO) and (lowest unoccupied molecular orbital) LUMO energy levels of the first compound, the second compound, and the third compound may each be a negative value, and the HOMO and LUMO energy levels may each be an actual measurement value; or a value evaluated or calculated according to a density functional theory (DFT) method.


In one or more embodiments, the absolute value of a difference between the LUMO energy level of the first compound and the LUMO energy level of the second compound may be about 0.1 eV or higher and about 1.0 eV or lower, the absolute value of a difference between the LUMO energy level of the first compound and the LUMO energy level of the third compound may be about 0.1 eV or higher and about 1.0 eV or lower, the absolute value of a difference between the HOMO energy level of the first compound and the HOMO energy level of the second compound may be 1.25 eV or lower (e.g., about 1.25 eV or lower and about 0.2 eV or higher), and the absolute value of a difference between the HOMO energy level of the first compound and the HOMO energy level of the third compound may be 1.25 eV or lower (e.g., about 1.25 eV or lower and about 0.2 eV or higher).


When the relationships between LUMO energy level and HOMO energy level satisfy the conditions as described above, the balance between holes and electrons injected into the emission layer can be made.


The light-emitting device may have a structure of a first embodiment or a second embodiment. The first embodiment or the second embodiment is the same as described in the present specification.


Descriptions of First Embodiment

According to the first embodiment, the first compound may be included in an emission layer in an interlayer of a light-emitting device, wherein the emission layer may further include a host, the first compound may be different from the host, and the emission layer may emit phosphorescence or fluorescence from the first compound. For example, according to the first embodiment, the first compound may be a dopant or an emitter. In some embodiments, the first compound may be a phosphorescent dopant or a phosphorescence emitter.


Phosphorescence or fluorescence emitted from the first compound may be blue light.


The emission layer may further include an ancillary dopant. The ancillary dopant may serve to improve luminescence efficiency from the first compound by effectively transferring energy to a dopant or the first compound as an emitter.


The ancillary dopant may be different from the first compound and the host.


In some embodiments, the ancillary dopant may be a delayed fluorescence-emitting compound.


In some embodiments, the ancillary dopant may be a compound including at least one cyclic group including boron (B) and nitrogen (N) as ring-forming atoms.


Descriptions of Second Embodiment

According to the second embodiment, the first compound may be included in an emission layer in an interlayer of a light-emitting device, wherein the emission layer may further include a host and a dopant, the first compound may be different from the host and the dopant, and the emission layer may emit phosphorescence or fluorescence (e.g., delayed fluorescence) from the dopant.


In an embodiment, the first compound in the second embodiment may serve as an ancillary dopant that transfers energy to a dopant (or an emitter), not as a dopant.


In some embodiments, the first compound in the second embodiment may serve as an emitter and as an ancillary dopant that transfers energy to a dopant (or an emitter).


In an embodiment, phosphorescence or fluorescence emitted from the dopant (or the emitter) in the second embodiment may be blue phosphorescence or blue fluorescence (e.g., blue delayed fluorescence).


The dopant (or the emitter) in the second embodiment may be a phosphorescent dopant material (e.g., the organometallic compound represented by Formula 1, the organometallic compound represented by Formula 401, or any combination thereof) or any suitable fluorescent dopant material (e.g., the compound represented by Formula 501, the compound represented by Formula 502, the compound represented by Formula 503, or any combination thereof).


In the first embodiment and the second embodiment, the blue light may be blue light having a maximum emission wavelength in a range of about 430 nanometers (nm) to about 490 nm, about 430 nm to about 485 nm, about 440 nm to about 475 nm, or about 455 nm to about 470 nm.


The ancillary dopant in the first embodiment may include, e.g. the fourth compound represented by Formula 502 or 503.


The host in the first embodiment and the second embodiment may be any suitable host material (e.g., the compound represented by Formula 301, the compound represented by 301-1, the compound represented by Formula 301-2, or any combination thereof).


In some embodiments, the host in the first embodiment and the second embodiment may be the second compound, the third compound, or any combination thereof.


In an embodiment, the light-emitting device may further include at least one of a first capping layer outside the first electrode and/or a second capping layer outside the second electrode, and the at least one of the first capping layer and/or the second capping layer may include the organometallic compound represented by Formula 1-1 or 1-2. More details for the first capping layer and/or second capping layer are the same as described in the present specification.


In an embodiment, the light-emitting device may further include:

  • a first capping layer outside the first electrode and including the organometallic compound represented by Formula 1-1 or 1-2;
  • a second capping layer outside the second electrode and including the organometallic compound represented by Formula 1-1 or 1-2; or
  • the first capping layer and the second capping layer (each including the organometallic compound represented by Formula 1-1 or 1-2).


The wording “(interlayer and/or capping layer) includes an organometallic compound” as used herein may be understood as “(interlayer and/or capping layer) may include one kind of organometallic compound represented by Formula 1-1 or 1-2 or two different kinds of organometallic compounds, each represented by Formula 1-1 or 1-2.”


In an embodiment, the interlayer and/or capping layer may include Compound 1 only as the organometallic compound. In this regard, Compound 1 may be present in the emission layer of the light-emitting device. In one or more embodiments, the interlayer may include, as the organometallic compound, Compound 1 and Compound 2. In this regard, Compound 1 and Compound 2 may be present in the same layer (for example, all of Compound 1 and Compound 2 may be present in the emission layer), or may be present in different layers (for example, Compound 1 may be present in the emission layer, and Compound 2 may be present in the electron transport region).


The term “interlayer,” as used herein, refers to a single layer and/or all of a plurality of layers between the first electrode and the second electrode of the light-emitting device.


Description of FIG. 1


FIG. 1 is a schematic cross-sectional view of a light-emitting device 10 according to an embodiment of the disclosure. The light-emitting device 10 includes a first electrode 110, an interlayer 130, and a second electrode 150.


Hereinafter, a structure of the light-emitting device 10 according to an embodiment and a method of manufacturing the light-emitting device 10 will be described in connection with FIG. 1.


First Electrode 110

In FIG. 1, a substrate may be additionally under the first electrode 110 or above the second electrode 150. As the substrate, a glass substrate and/or a plastic substrate may be used. In an embodiment, the substrate may be a flexible substrate, and may include plastics having excellent heat resistance and durability, such as polyimide, polyethylene terephthalate (PET), polycarbonate, polyethylene naphthalate, polyarylate (PAR), polyetherimide, or any combination thereof.


The first electrode 110 may be formed by, for example, depositing and/or sputtering a material for forming the first electrode 110 on the substrate. When the first electrode 110 is an anode, a material for forming the first electrode 110 may be a high work function material that facilitates injection of holes.


The first electrode 110 may be a reflective electrode, a semi-transmissive electrode, or a transmissive electrode. When the first electrode 110 is a transmissive electrode, a material for forming the first electrode 110 may include indium tin oxide (ITO), indium zinc oxide (IZO), tin oxide (SnO2), zinc oxide (ZnO), or any combinations thereof. In one or more embodiments, when the first electrode 110 is a semi-transmissive electrode or a reflective electrode, magnesium (Mg), silver (Ag), aluminum (Al), aluminum-lithium (Al—Li), calcium (Ca), magnesium-indium (Mg—In), magnesium-silver (Mg—Ag), or any combinations thereof may be used as a material for forming a first electrode.


The first electrode 110 may have a single-layered structure consisting of a single layer or a multilayer structure including a plurality of layers. In an embodiment, the first electrode 110 may have a three-layered structure of ITO/Ag/ITO.


Interlayer 130

The interlayer 130 may be on the first electrode 110. The interlayer 130 may include an emission layer.


The interlayer 130 may further include a hole transport region between the first electrode 110 and the emission layer and an electron transport region between the emission layer and the second electrode 150.


The interlayer 130 may further include metal-containing compounds such as organometallic compounds, inorganic materials such as quantum dots, and/or the like, in addition to various suitable organic materials.


In one or more embodiments, the interlayer 130 may include, i) two or more emitting units sequentially stacked between the first electrode 110 and the second electrode 150, and ii) a charge generation layer between the two emitting units. When the interlayer 130 includes emitting units and a charge generation layer as described above, the light-emitting device 10 may be a tandem light-emitting device.


Hole Transport Region in Interlayer 130

The hole transport region may have: i) a single-layered structure consisting of a single layer consisting of a single material, ii) a single-layered structure consisting of a single layer consisting of a plurality of different materials, or iii) a multi-layered structure including a plurality of layers including different materials.


The hole transport region may include a hole injection layer, a hole transport layer, an emission auxiliary layer, an electron blocking layer, or any combination thereof.


For example, the hole transport region may have a multi-layered structure including a hole injection layer/hole transport layer structure, a hole injection layer/hole transport layer/emission auxiliary layer structure, a hole injection layer/emission auxiliary layer structure, a hole transport layer/emission auxiliary layer structure, or a hole injection layer/hole transport layer/electron blocking layer structure, the layers of each structure being stacked sequentially from the first electrode 110.


The hole transport region may include a compound represented by Formula 201, a compound represented by Formula 202, or any combination thereof:




embedded image - Formula 201




embedded image - Formula 202


wherein, in Formulae 201 and 202,

  • L201 to L204 may each independently be a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,
  • L205 may be *—O—*’, *—S—*’, *—N(Q201)—*’, a C1-C20 alkylene group unsubstituted or substituted with at least one R10a, a C2-C20 alkenylene group unsubstituted or substituted with at least one R10a, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,
  • xa1 to xa4 may each independently be an integer from 0 to 5,
  • xa5 may be an integer from 1 to 10,
  • R201 to R204 and Q201 may each independently be a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,
  • R201 and R202 may optionally be linked to each other, via a single bond, a C1-C5 alkylene group unsubstituted or substituted with at least one R10a, or a C2-C5 alkenylene group unsubstituted or substituted with at least one R10a, to form a C8-C60 polycyclic group (for example, a carbazole group or the like) unsubstituted or substituted with at least one R10a (for example, Compound HT16),
  • R203 and R204 may optionally be linked to each other via a single bond, a C1-C5 alkylene group unsubstituted or substituted with at least one R10a, or a C2-C5 alkenylene group unsubstituted or substituted with at least one R10a, to form a C8-C60 polycyclic group unsubstituted or substituted with at least one R10a, and
  • na1 may be an integer from 1 to 4.


In an embodiment, each of Formulae 201 and 202 may include at least one of groups represented by Formulae CY201 to CY217.




embedded image - CY201




embedded image - CY202




embedded image - CY203




embedded image - CY204 CY205




embedded image - CY206




embedded image - CY207




embedded image - CY208 CY209




embedded image - CY210




embedded image - CY211




embedded image - CY212




embedded image - CY213




embedded image - CY214




embedded image - CY215




embedded image - CY216




embedded image - CY217


wherein in Formulae CY201 to CY217, R10b and R10c may each be the same as described with respect to R10a, ring CY201 to ring CY204 may each independently be a C3-C20 carbocyclic group or a C1-C20 heterocyclic group, and at least one hydrogen in Formulae CY201 to CY217 may be unsubstituted or substituted with R10a as described above.


In an embodiment, ring CY201 to ring CY204 in Formulae CY201 to CY217 may each independently be a benzene group, a naphthalene group, a phenanthrene group, or an anthracene group.


In an embodiment, each of Formulae 201 and 202 may include at least one of groups represented by Formulae CY201 to CY203.


In an embodiment, Formula 201 may include at least one of groups represented by Formulae CY201 to CY203 and at least one of groups represented by Formulae CY204 to CY217.


In an embodiment, xa1 in Formula 201 may be 1, R201 may be a group represented by one of Formulae CY201 to CY203, xa2 may be 0, and R202 may be a group represented by one of Formulae CY204 to CY207.


In an embodiment, each of Formulae 201 and 202 may not include groups represented by Formulae CY201 to CY203.


In an embodiment, each of Formulae 201 and 202 may not include groups represented by Formulae CY201 to CY203, and may include at least one of groups represented by Formulae CY204 to CY217.


In an embodiment, each of Formulae 201 and 202 may not include groups represented by Formulae CY201 to CY217.


In an embodiment, the hole transport region may include one of Compounds HT1 to HT46, m-MTDATA, TDATA, 2-TNATA, NPB(NPD), β-NPB, TPD, Spiro-TPD, Spiro-NPB, methylated NPB, TAPC, HMTPD, 4,4',4″-tris(N-carbazolyl)triphenylamine (TCTA), polyaniline/dodecylbenzenesulfonic acid (PANI/DBSA), poly(3,4-ethylenedioxythiophene)/poly(4-styrenesulfonate) (PEDOT/PSS), polyaniline/camphor sulfonic acid (PANI/CSA), polyaniline/poly(4-styrenesulfonate) (PANI/PSS), or any combination thereof:




embedded image - HT1




embedded image - HT2




embedded image - HT3




embedded image - HT4




embedded image - HT5




embedded image - HT6




embedded image - HT7




embedded image - HT8




embedded image - HT9




embedded image - HT10




embedded image - HT11




embedded image - HT12




embedded image - HT13




embedded image - HT14




embedded image - HT15




embedded image - HT16




embedded image - HT17




embedded image - HT18




embedded image - HT19




embedded image - HT20




embedded image - HT21




embedded image - HT22




embedded image - HT23




embedded image - HT24




embedded image - HT25




embedded image - HT26




embedded image - HT27




embedded image - HT28




embedded image - HT29




embedded image - HT30




embedded image - HT31




embedded image - HT32




embedded image - HT33




embedded image - HT34




embedded image - HT35




embedded image - HT36




embedded image - HT37




embedded image - HT38




embedded image - HT39




embedded image - HT40




embedded image - HT41




embedded image - HT42




embedded image - HT43




embedded image - HT44




embedded image - HT45




embedded image - HT46




embedded image - m-MTDATA




embedded image - TDATA




embedded image - 2-TNATA




embedded image - NPB




embedded image - β-NPB TPD




embedded image - Spiro-TPD




embedded image - Spiro-NPB




embedded image - methylated-NPB




embedded image - TAPC




embedded image - HMTPD


A thickness of the hole transport region may be in a range of about 50 Å to about 10,000 Å, for example, about 100 Å to about 4,000 Å. When the hole transport region includes a hole injection layer, a hole transport layer, or any combination thereof, a thickness of the hole injection layer may be in a range of about 100 Å to about 9,000 Å, for example, about 100 Å to about 1,000 Å, and a thickness of the hole transport layer may be in a range of about 50 Å to about 2,000 Å, for example, about 100 Å to about 1,500 Å. When the thicknesses of the hole transport region, the hole injection layer and the hole transport layer are within these ranges, suitable or satisfactory hole-transporting characteristics may be obtained without a substantial increase in driving voltage.


The emission auxiliary layer may increase light-emission efficiency by compensating for an optical resonance distance according to the wavelength of light emitted by an emission layer, and the electron blocking layer may block or reduce the leakage of electrons from an emission layer to a hole transport region. Materials that may be included in the hole transport region may be included in the emission auxiliary layer and the electron blocking layer.


P-Dopant

The hole transport region may further include, in addition to these materials, a charge-generation material for the improvement of conductive properties (e.g., electrically conductive properties). The charge-generation material may be uniformly or non-uniformly dispersed in the hole transport region (for example, in the form of a single layer consisting of a charge-generation material).


The charge-generation material may be, for example, a p-dopant.


In an embodiment, a LUMO energy level of the p-dopant may be about -3.5 eV or less.


In an embodiment, the p-dopant may include a quinone derivative, a cyano group-containing compound, a compound containing element EL1 and element EL2, or any combination thereof.


Examples of the quinone derivative may include TCNQ, F4-TCNQ, and the like.


Examples of the cyano group-containing compound may include HAT-CN, a compound represented by Formula 221 below, and the like.




embedded image




embedded image




embedded image - Formula 221




embedded image


In Formula 221,

  • R221 to R223 may each independently be a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, and
  • at least one of R221 to R223 may each independently be a C3-C60 carbocyclic group or a C1-C60 heterocyclic group, each substituted with: a cyano group; —F; —Cl; —Br; —l; a C1-C20 alkyl group substituted with a cyano group, —F, —Cl, —Br, —l, or any combination thereof; or any combination thereof.


In the compound containing element EL1 and element EL2, element EL1 may be metal, metalloid, or a combination thereof, and element EL2 may be non-metal, metalloid, or a combination thereof.


Examples of the metal may include: an alkali metal (for example, lithium (Li), sodium (Na), potassium (K), rubidium (Rb), cesium (Cs), etc.); an alkaline earth metal (for example, beryllium (Be), magnesium (Mg), calcium (Ca), strontium (Sr), barium (Ba), etc.); a transition metal (for example, titanium (Ti), zirconium (Zr), hafnium (Hf), vanadium (V), niobium (Nb), tantalum (Ta), chromium (Cr), molybdenum (Mo), tungsten (W), manganese (Mn), technetium (Tc), rhenium (Re), iron (Fe), ruthenium (Ru), osmium (Os), cobalt (Co), rhodium (Rh), iridium (Ir), nickel (Ni), palladium (Pd), platinum (Pt), copper (Cu), silver (Ag), gold (Au), etc.); a post-transition metal (for example, zinc (Zn), indium (In), tin (Sn), etc.); and a lanthanide metal (for example, lanthanum (La), cerium (Ce), praseodymium (Pr), neodymium (Nd), promethium (Pm), samarium (Sm), europium (Eu), gadolinium (Gd), terbium (Tb), dysprosium (Dy), holmium (Ho), erbium (Er), thulium (Tm), ytterbium (Yb), lutetium (Lu), etc.).


Examples of the metalloid may include silicon (Si), antimony (Sb), and tellurium (Te).


Examples of the non-metal may include oxygen (O) and halogen (for example, F, Cl, Br, I, etc.).


In an embodiment, examples of the compound containing element EL1 and element EL2 may include metal oxide, metal halide (for example, metal fluoride, metal chloride, metal bromide, or metal iodide), metalloid halide (for example, metalloid fluoride, metalloid chloride, metalloid bromide, or metalloid iodide), metal telluride, or any combination thereof.


Examples of the metal oxide may include tungsten oxide (for example, WO, W2O3, WO2, WO3, W2O5, etc.), vanadium oxide (for example, VO, V2O3, VO2, V2O5, etc.), molybdenum oxide (MoO, Mo2O3, MoO2, MoO3, Mo2O5, etc.), and rhenium oxide (for example, ReO3, etc.).


Examples of the metal halide may include alkali metal halide, alkaline earth metal halide, transition metal halide, post-transition metal halide, and lanthanide metal halide.


Examples of the alkali metal halide may include LiF, NaF, KF, RbF, CsF, LiCl, NaCl, KCl, RbCl, CsCl, LiBr, NaBr, KBr, RbBr, CsBr, Lil, Nal, Kl, Rbl, and Csl.


Examples of the alkaline earth metal halide may include BeF2, MgF2, CaF2, SrF2, BaF2, BeCl2, MgCl2, CaCl2, SrCl2, BaCl2, BeBr2, MgBr2, CaBr2, SrBr2, BaBr2, Bel2, Mgl2, Cal2, Srl2, and Bal2.


Examples of the transition metal halide may include titanium halide (for example, TiF4, TiCl4, TiBr4, Til4, etc.), zirconium halide (for example, ZrF4, ZrCl4, ZrBr4, Zrl4, etc.), hafnium halide (for example, HfF4, HfCl4, HfBr4, Hfl4, etc.), vanadium halide (for example, VF3, VCl3, VBr3, Vl3, etc.), niobium halide (for example, NbF3, NbCl3, NbBr3, Nbl3, etc.), tantalum halide (for example, TaF3, TaCl3, TaBr3, Tals, etc.), chromium halide (for example, CrF3, CrCl3, CrBr3, Crl3, etc.), molybdenum halide (for example, MoF3, MoCl3, MoBr3, Mols, etc.), tungsten halide (for example, WF3, WCl3, WBr3, Wl3, etc.), manganese halide (for example, MnF2, MnCl2, MnBr2, Mnl2, etc.), technetium halide (for example, TcF2, TcCl2, TcBr2, Tcl2, etc.), rhenium halide (for example, ReF2, ReCl2, ReBr2, Rel2, etc.), iron halide (for example, FeF2, FeCl2, FeBr2, Fel2, etc.), ruthenium halide (for example, RuF2, RuCl2, RuBr2, Rul2, etc.), osmium halide (for example, OsF2, OsCl2, OsBr2, Osl2, etc.), cobalt halide (for example, CoF2, CoCl2, CoBr2, Col2, etc.), rhodium halide (for example, RhF2, RhCl2, RhBr2, Rhl2, etc.), iridium halide (for example, IrF2, IrCl2, IrBr2, Irl2, etc.), nickel halide (for example, NiF2, NiCl2, NiBr2, Nil2, etc.), palladium halide (for example, PdF2, PdCl2, PdBr2, Pdl2, etc.), platinum halide (for example, PtF2, PtCl2, PtBr2, Ptl2, etc.), copper halide (for example, CuF, CuCl, CuBr, Cul, etc.), silver halide (for example, AgF, AgCl, AgBr, Agl, etc.), and gold halide (for example, AuF, AuCl, AuBr, Aul, etc.).


Examples of the post-transition metal halide may include zinc halide (for example, ZnF2, ZnCl2, ZnBr2, Znl2, etc.), indium halide (for example, Inl3, etc.), and tin halide (for example, Snl2, etc.).


Examples of the lanthanide metal halide may include YbF, YbF2, YbF3, SmF3, YbCl, YbCl2, YbCl3 SmCl3, YbBr, YbBr2, YbBr3, SmBr3, Ybl, Ybl2, Ybl3, and Sml3.


Examples of the metalloid halide may include antimony halide (for example, SbCl5, etc.).


Examples of the metal telluride may include alkali metal telluride (for example, Li2Te, Na2Te, K2Te, Rb2Te, Cs2Te, etc.), alkaline earth metal telluride (for example, BeTe, MgTe, CaTe, SrTe, BaTe, etc.), transition metal telluride (for example, TiTe2, ZrTe2, HfTe2, V2Te3, Nb2Tes, Ta2Te3, Cr2Te3, Mo2Tes, W2Te3, MnTe, TcTe, ReTe, FeTe, RuTe, OsTe, CoTe, RhTe, IrTe, NiTe, PdTe, PtTe, Cu2Te, CuTe, Ag2Te, AgTe, Au2Te, etc.), post-transition metal telluride (for example, ZnTe, etc.), and lanthanide metal telluride (for example, LaTe, CeTe, PrTe, NdTe, PmTe, EuTe, GdTe, TbTe, DyTe, HoTe, ErTe, TmTe, YbTe, LuTe, etc.).


Emission Layer in Interlayer 130

When the light-emitting device 10 is a full-color light-emitting device, the emission layer may be patterned into a red emission layer, a green emission layer, and/or a blue emission layer, according to a sub-pixel. In an embodiment, the emission layer may have a stacked structure of two or more layers of a red emission layer, a green emission layer, and a blue emission layer, in which the two or more layers contact each other (e.g., physically contact each other) or are separated from each other (e.g., are spaced apart from each other). In one or more embodiments, the emission layer may include two or more materials of a red light-emitting material, a green light-emitting material, and a blue light-emitting material, in which the two or more materials are mixed together with each other in a single layer to emit white light.


The emission layer may include a host and a dopant. The dopant may include a phosphorescent dopant, a fluorescent dopant, or any combination thereof.


An amount of the dopant in the emission layer may be from about 0.01 parts by weight to about 15 parts by weight based on 100 parts by weight of the host.


In an embodiment, the emission layer may include a quantum dot.


In an embodiment, the emission layer may include a delayed fluorescence material. The delayed fluorescence material may act as a host or a dopant in the emission layer.


A thickness of the emission layer may be in a range of about 100 Å to about 1,000 Å, for example, about 200 Å to about 600 Å. When the thickness of the emission layer is within the above ranges, excellent light-emission characteristics may be obtained without a substantial increase in driving voltage.


Host

The host may include a compound represented by Formula 301 below:




embedded image - Formula 301


wherein, in Formula 301,

  • Ar301 and L301 may each independently be a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,
  • xb11 may be 1, 2, or 3,
  • xb1 may be an integer from 0 to 5,
  • R301 may be hydrogen, deuterium, —F, —Cl, —Br, —l, a hydroxyl group, a cyano group, a nitro group, a C1-C60 alkyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkenyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkynyl group unsubstituted or substituted with at least one R10a, a C1-C60 alkoxy group unsubstituted or substituted with at least one R10a, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,—Si(Q301)(Q302)(Q303), —N(Q301)(Q302), —B(Q301)(Q302), —C(═O)(Q301), —S(═O)2(Q301), or —P(═O)(Q301)(Q302),
  • xb21 may be an integer from 1 to 5, and
  • Q301 to Q303 are the same as described in connection with Q1.


In an embodiment, when xb11 in Formula 301 is 2 or more, two or more of Ar301(s) may be linked to each other via a single bond.


In an embodiment, the host may include a compound represented by Formula 301-1, a compound represented by Formula 301-2, or any combination thereof:




embedded image - Formula 301-1




embedded image - Formula 301-2


wherein, in Formulae 301-1 and 301-2,

  • ring A301 to ring A304 may each independently be a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,
  • X301 may be O, S, N-[(L304)xb4-R304], C(R304)(R305), or Si(R304)(R305),
  • xb22 and xb23 may each independently be 0, 1, or 2,
  • L301, xb1, and R301 are the same as described in the present specification,
  • L302 to L304 are each independently the same as described in connection with L301,
  • xb2 to xb4 are each independently the same as described in connection with xb1, and
  • R302 to R305 and R311 to R314 are the same as described in connection with R301.


In an embodiment, the host may include an alkali earth metal complex, a post-transition metal complex, or a combination thereof. In an embodiment, the host may include a Be complex (for example, Compound H55), an Mg complex, a Zn complex, or a combination thereof.


In an embodiment, the host may include one of Compounds H1 to H124, 9,10-di(2-naphthyl)anthracene (ADN), 2-methyl-9,10-bis(naphthalen-2-yl)anthracene (MADN), 9,10-di-(2-naphthyl)-2-t-butyl-anthracene (TBADN), 4,4′-bis(N-carbazolyl)-1,1′-biphenyl (CBP), 1,3-di-9-carbazolylbenzene (mCP), 1,3,5-tri(carbazol-9-yl)benzene (TCP), or any combination thereof:




embedded image - H1




embedded image - H2




embedded image - H3




embedded image - H4




embedded image - H5




embedded image - H6




embedded image - H7




embedded image - H8




embedded image - H9




embedded image - H10




embedded image - H11




embedded image - H12




embedded image - H13




embedded image - H14




embedded image - H15




embedded image - H16




embedded image - H17




embedded image - H18




embedded image - H19




embedded image - H20




embedded image - H21




embedded image - H22




embedded image - H23




embedded image - H24




embedded image - H25




embedded image - H26




embedded image - H27




embedded image - H28




embedded image - H29




embedded image - H30




embedded image - H31




embedded image - H32




embedded image - H33




embedded image - H34




embedded image - H35




embedded image - H36




embedded image - H37




embedded image - H38




embedded image - H39




embedded image - H40




embedded image - H41




embedded image - H42




embedded image - H43




embedded image - H44




embedded image - H45




embedded image - H46




embedded image - H47




embedded image - H48




embedded image - H49




embedded image - H50




embedded image - H51




embedded image - H52




embedded image - H53




embedded image - H54




embedded image - H55




embedded image - H56




embedded image - H57




embedded image - H58




embedded image - H59




embedded image - H60




embedded image - H61




embedded image - H62




embedded image - H63




embedded image - H64




embedded image - H65




embedded image - H66




embedded image - H67




embedded image - H68




embedded image - H69




embedded image - H70




embedded image - H71




embedded image - H72




embedded image - H73




embedded image - H74




embedded image - H75




embedded image - H76




embedded image - H77




embedded image - H78




embedded image - H79




embedded image - H80




embedded image - H81




embedded image - H82




embedded image - H83




embedded image - H84




embedded image - H85




embedded image - H86




embedded image - H87




embedded image - H88




embedded image - H89




embedded image - H90




embedded image - H91




embedded image - H92




embedded image - H93




embedded image - H94




embedded image - H95




embedded image - H96




embedded image - H97




embedded image - H98




embedded image - H99




embedded image - H100




embedded image - H101




embedded image - H102




embedded image - H103




embedded image - H104




embedded image - H105




embedded image - H106




embedded image - H107




embedded image - H108




embedded image - H109




embedded image - H110




embedded image - H111




embedded image - H112




embedded image - H113




embedded image - H114




embedded image - H115




embedded image - H116




embedded image - H117




embedded image - H118




embedded image - H119




embedded image - H120




embedded image - H121




embedded image - H122




embedded image - H123




embedded image - H124


Phosphorescent Dopant

The phosphorescent dopant may include at least one transition metal as a central metal atom.


The phosphorescent dopant may include a monodentate ligand, a bidentate ligand, a tridentate ligand, a tetradentate ligand, a pentadentate ligand, a hexadentate ligand, or any combination thereof.


The phosphorescent dopant may be electrically neutral.


In an embodiment, the phosphorescent dopant may include an organometallic compound represented by Formula 401:




embedded image - Formula 401




embedded image - Formula 402


wherein, in Formulae 401 and 402,

  • M may be a transition metal (for example, iridium (Ir), platinum (Pt), palladium (Pd), osmium (Os), titanium (Ti), gold (Au), hafnium (Hf), europium (Eu), terbium (Tb), rhodium (Rh), rhenium (Re), or thulium (Tm)),
  • L401 may be a ligand represented by Formula 402, and xc1 may be 1, 2, or 3, wherein, when xc1 is two or more, two or more of L401(s) may be identical to or different from each other,
  • L402 may be an organic ligand, and xc2 may be 0, 1, 2, 3, or 4, wherein, when xc2 is 2 or more, two or more of L402(s) may be identical to or different from each other,
  • X401 and X402 may each independently be nitrogen or carbon,
  • ring A401 and ring A402 may each independently be a C3-C60 carbocyclic group or a C1-C60 heterocyclic group,
  • T401 may be a single bond, *—O—*’, *—S—*’, *—C(═O)—*’, *—N(Q411)—*’, *—C(Q411)(Q412)—*’, *—C(Q411)═C(Q412)—*’, *—C(Q411)═*’, or *═C(Q411)═*’,
  • X403 and X404 may each independently be a chemical bond (for example, a covalent bond or a coordinate bond), O, S, N(Q413), B(Q413), P(Q413), C(Q413)(Q414), or Si(Q413)(Q414),
  • Q411 to Q414 are the same as described in connection with Q1,
  • R401 and R402 may each independently be hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C20 alkyl group unsubstituted or substituted with at least one R10a, a C1-C20 alkoxy group unsubstituted or substituted with at least one R10a, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, —Si(Q401)(Q402)(Q403), —N(Q401)(Q402), —B(Q401)(Q402), —C(═O)(Q401), —S(═O)2(Q401), or —P(═O)(Q401)(Q402),
  • Q401 to Q403 are the same as described in connection with Q1,
  • xc11 and xc12 may each independently be an integer from 0 to 10, and
  • * and *’ in Formula 402 each indicate a binding site to M in Formula 401.


In an embodiment, in Formula 402, i) X401 may be nitrogen, and X402 may be carbon, or ii) each of X401 and X402 may be nitrogen.


In an embodiment, when xc1 in Formula 402 is 2 or more, two ring A401 in two or more of L401(s) may be optionally linked to each other via T402, which is a linking group, and two ring A402 may optionally be linked to each other via T403, which is a linking group (see Compounds PD1 to PD4 and PD7). T402 and T403 are the same as described in connection with T401.


L402 in Formula 401 may be an organic ligand. In an embodiment, L402 may include a halogen group, a diketone group (for example, an acetylacetonate group), a carboxylic acid group (for example, a picolinate group), —C(═O), an isonitrile group, —CN group, a phosphorus group (for example, a phosphine group, a phosphite group, etc.), or any combination thereof.


The phosphorescent dopant may include, for example, one of compounds PD1 to PD39, or any combination thereof:




embedded image - PD1




embedded image - PD2




embedded image - PD3




embedded image - PD4




embedded image - PD5




embedded image - PD6




embedded image - PD7




embedded image - PD8




embedded image - PD9




embedded image - PD10




embedded image - PD11




embedded image - PD12




embedded image - PD13




embedded image - PD14




embedded image - PD15




embedded image - PD16




embedded image - PD17




embedded image - PD18




embedded image - PD19




embedded image - PD20




embedded image - PD21




embedded image - PD22




embedded image - PD23




embedded image - PD24




embedded image - PD25




embedded image - PD26




embedded image - PD27




embedded image - PD28




embedded image - PD29




embedded image - PD30




embedded image - PD31




embedded image - PD32




embedded image - PD33




embedded image - PD34




embedded image - PD35




embedded image - PD36




embedded image - PD37




embedded image - PD38




embedded image - PD39


Fluorescent Dopant

The fluorescent dopant may include an amine group-containing compound, a styryl group-containing compound, or any combination thereof.




embedded image - Formula 501


wherein, in Formula 501,

  • Ar501, L501 to L503, R501, and R502 may each independently be a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,
  • xd1 to xd3 may each independently be 0, 1, 2, or 3, and
  • xd4 may be 1, 2, 3, 4, 5, or 6.


In an embodiment, Ar501 in Formula 501 may be a condensed cyclic group (for example, an anthracene group, a chrysene group, or a pyrene group) in which three or more monocyclic groups are condensed together.


In an embodiment, xd4 in Formula 501 may be 2.


In an embodiment, the fluorescent dopant may include: one of Compounds FD1 to FD36; DPVBi; DPAVBi; or any combination thereof:




embedded image - FD1




embedded image - FD2




embedded image - FD3




embedded image - FD4




embedded image - FD5 FD6




embedded image - FD7




embedded image - FD8




embedded image - FD9




embedded image - FD10




embedded image - FD11




embedded image - FD12




embedded image - FD13




embedded image - FD14




embedded image - FD15




embedded image - FD16




embedded image - FD17




embedded image - FD18




embedded image - FD19




embedded image - FD20




embedded image - FD21




embedded image - FD22




embedded image




embedded image - FD25 FD26




embedded image - FD27




embedded image




embedded image - FD30




embedded image - FD31




embedded image




embedded image




embedded image - FD34




embedded image - FD35 FD36




embedded image - DPVBi




embedded image - DPAVBi


Delayed Fluorescence Material

The emission layer may include a delayed fluorescence material.


In the present specification, the delayed fluorescence material may be selected from compounds capable of emitting delayed fluorescence based on a delayed fluorescence emission mechanism.


The delayed fluorescence material included in the emission layer may act as a host or a dopant depending on the type or kind of other materials included in the emission layer.


In an embodiment, the difference between the triplet energy level (eV) of the delayed fluorescence material and the singlet energy level (eV) of the delayed fluorescence material may be greater than or equal to 0 eV and less than or equal to 0.5 eV. When the difference between the triplet energy level (eV) of the delayed fluorescence material and the singlet energy level (eV) of the delayed fluorescence material satisfies the above-described range, up-conversion from the triplet state to the singlet state of the delayed fluorescence materials may effectively occur, and thus, the luminescence efficiency of the light-emitting device 10 may be improved.


In an embodiment, the delayed fluorescence material may include i) a material including at least one electron donor (for example, a π electron-rich C3-C60 cyclic group, such as a carbazole group) and at least one electron acceptor (for example, a sulfoxide group, a cyano group, or a π electron-deficient nitrogen-containing C1-C60 cyclic group), and ii) a material including a C8-C60 polycyclic group in which two or more cyclic groups are condensed together while sharing boron (B).


Examples of the delayed fluorescence material may include at least one of the following Compounds DF1 to DF9:




embedded image - (DMAC-DPS)




embedded image - (ACRFLCN)




embedded image - (ACRSA)




embedded image - (CC2TA)




embedded image - (PIC-TRZ)




embedded image - (PIC-TRZ2)




embedded image - (PXZ-TRZ)




embedded image - (DABNA-1)




embedded image - (DABNA-2)


Quantum Dot

The emission layer may include a quantum dot.


In the present specification, a quantum dot refers to a crystal of a semiconductor compound, and may include any suitable material capable of emitting light of various suitable emission wavelengths according to the size of the crystal.


A diameter of the quantum dot may be, for example, in a range of about 1 nm to about 10 nm.


The quantum dot may be synthesized by a wet chemical process, a metal organic chemical vapor deposition process, a molecular beam epitaxy process, and/or any suitable process similar thereto.


According to the wet chemical process, a precursor material is mixed together with an organic solvent to grow a quantum dot particle crystal. When the crystal grows, the organic solvent naturally acts as a dispersant coordinated on the surface of the quantum dot crystal and controls the growth of the crystal so that the growth of quantum dot particles may be controlled through a process which is more easily performed than vapor deposition methods, such as metal organic chemical vapor deposition (MOCVD) or molecular beam epitaxy (MBE), and which requires low costs.


The quantum dot may include: a Group II-VI semiconductor compound; a Group III-V semiconductor compound; a Group III-VI semiconductor compound; a Group I-III-VI semiconductor compound; a Group IV-VI semiconductor compound; a Group IV element or compound; or any combination thereof.


Examples of the Group II-VI semiconductor compound may include: a binary compound, such as CdSe, CdTe, ZnS, ZnSe, ZnTe, ZnO, HgS, HgSe, HgTe, MgSe, or MgS; a ternary compound, such as CdSeS, CdSeTe, CdSTe, ZnSeS, ZnSeTe, ZnSTe, HgSeS, HgSeTe, HgSTe, CdZnS, CdZnSe, CdZnTe, CdHgS, CdHgSe, CdHgTe, HgZnS, HgZnSe, HgZnTe, MgZnSe, or MgZnS; a quaternary compound, such as CdZnSeS, CdZnSeTe, CdZnSTe, CdHgSeS, CdHgSeTe, CdHgSTe, HgZnSeS, HgZnSeTe, or HgZnSTe; or any combination thereof.


Examples of the Group III-V semiconductor compound may include: a binary compound, such as GaN, GaP, GaAs, GaSb, AIN, AIP, AlAs, AlSb, InN, InP, InAs, or InSb; a ternary compound, such as GaNP, GaNAs, GaNSb, GaPAs, GaPSb, AlNP, AlNAs, AlNSb, AlPAs, AlPSb, InGaP, InNP, InAIP, InNAs, InNSb, InPAs, or InPSb; a quaternary compound, such as GaAINP, GaAINAs, GaAINSb, GaAlPAs, GaAlPSb, GalnNP, GalnNAs, GalnNSb, GalnPAs, GalnPSb, InAlNP, InAlNAs, InAlNSb, InAlPAs, or InAlPSb; or any combination thereof. In an embodiment, the Group III-V semiconductor compound may further include Group II elements. Examples of the Group III-V semiconductor compound further including Group II elements may include InZnP, InGaZnP, InAlZnP, and the like.


Examples of the Group III-VI semiconductor compound may include: a binary compound, such as GaS, GaSe, Ga2Se3, GaTe, InS, InSe, In2S3, In2Se3, or InTe; a ternary compound, such as InGaS3, or InGaSe3; or any combination thereof.


Examples of the Group I-III-VI semiconductor compound may include: a ternary compound, such as AglnS, AglnS2, CulnS, CulnS2, CuGaO2, AgGaO2, or AgAlO2; or any combination thereof.


Examples of the Group IV-VI semiconductor compound may include: a binary compound, such as SnS, SnSe, SnTe, PbS, PbSe, PbTe, or the like; a ternary compound, such as SnSeS, SnSeTe, SnSTe, PbSeS, PbSeTe, PbSTe, SnPbS, SnPbSe, SnPbTe, or the like; a quaternary compound, such as SnPbSSe, SnPbSeTe, SnPbSTe, or the like; or any combination thereof.


The Group IV element or compound may include: a single element compound, such as Si or Ge; a binary compound, such as SiC or SiGe; or any combination thereof.


Each element included in a multi-element compound such as the binary compound, ternary compound and quaternary compound, may exist in a particle having a uniform concentration or non-uniform concentration.


In an embodiment, the quantum dot may have a single structure or a dual core-shell structure. In the case of the quantum dot having a single structure, the concentration of each element included in the corresponding quantum dot is uniform (e.g., substantially uniform). In an embodiment, the material contained in the core and the material contained in the shell may be different from each other.


The shell of the quantum dot may act as a protective layer to prevent or reduce chemical degeneration of the core to maintain semiconductor characteristics and/or as a charging layer to impart electrophoretic characteristics to the quantum dot. The shell may be a single layer or a multi-layer. The element presented in the interface between the core and the shell of the quantum dot may have a concentration gradient that decreases along a direction toward the center of the quantum dot.


Examples of the shell of the quantum dot may be an oxide of metal, metalloid, or non-metal, a semiconductor compound, and any combination thereof. Examples of the oxide of metal, metalloid, or non-metal may include: a binary compound, such as SiO2, Al2O3, TiO2, ZnO, MnO, Mn2O3, Mn3O4, CuO, FeO, Fe2O3, Fe3O4, CoO, Co3O4, or NiO; a ternary compound, such as MgAl2O4, CoFe2O4, NiFe2O4, or CoMn2O4; or any combination thereof. Examples of the semiconductor compound may include, as described herein, a Group II-VI semiconductor compound, a Group III-V semiconductor compound, a Group III-VI semiconductor compound, a Group I-III-VI semiconductor compound, a Group IV-VI semiconductor compound, or any combination thereof. In addition, the semiconductor compound may include CdS, CdSe, CdTe, ZnS, ZnSe, ZnTe, ZnSeS, ZnTeS, GaAs, GaP, GaSb, HgS, HgSe, HgTe, InAs, InP, InGaP, InSb, AlAs, AIP, AlSb, or any combination thereof.


A full width at half maximum (FWHM) of an emission wavelength spectrum of the quantum dot may be about 45 nm or less, for example, about 40 nm or less, for example, about 30 nm or less, and within these ranges, color purity or color reproducibility may be increased. In addition, because the light emitted through the quantum dot is emitted in all directions (or substantially all directions), the wide viewing angle can be improved.


In addition, the quantum dot may be a spherical particle, a pyramidal particle, a multi-arm particle, a cubic nanoparticle, a nanotube particle, a nanowire particle, a nanofiber particle, or a nanoplate particle.


Because the energy band gap can be adjusted by controlling the size of the quantum dot, light having various suitable wavelength bands can be obtained from the quantum dot emission layer. Therefore, by using quantum dots of different sizes, a light-emitting device that emits light of various suitable wavelengths may be implemented. In an embodiment, the size of the quantum dot may be selected to emit red, green and/or blue light. In addition, the size of the quantum dot may be configured to emit white light by combining light of various suitable colors.


Electron Transport Region in Interlayer 130

The electron transport region may have: i) a single-layered structure consisting of a single layer consisting of a single material, ii) a single-layered structure consisting of a single layer consisting of a plurality of different materials, or iii) a multi-layered structure including a plurality of layers including different materials.


The electron transport region may include a buffer layer, a hole blocking layer, an electron control layer, an electron transport layer, an electron injection layer, or any combination thereof.


For example, the electron transport region may have an electron transport layer/electron injection layer structure, a hole-blocking layer/electron transport layer/electron injection layer structure, an electron control layer/electron transport layer/electron injection layer structure, or a buffer layer/electron transport layer/electron injection layer structure, the constituting layers of each structure being sequentially stacked from an emission layer.


In an embodiment, the electron transport region (for example, the buffer layer, the hole-blocking layer, the electron control layer, or the electron transport layer in the electron transport region) may include a metal-free compound including at least one π electron-deficient nitrogen-containing C1-C60 cyclic group.


In an embodiment, the electron transport region may include a compound represented by Formula 601 below:




embedded image - Formula 601


wherein, in Formula 601,

  • Ar601 and L601 may each independently be a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,
  • xe11 may be 1, 2, or 3,
  • xe1 may be 0, 1, 2, 3, 4, or 5,
  • R601 may be a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, —Si(Q601)(Q602)(Q603), —C(═O)(Q601), —S(═O)2(Q601), or —P(═O)(Q601)(Q602),
  • Q601 to Q603 are the same as described in connection with Q1,
  • xe21 may be 1, 2, 3, 4, or 5, and
  • at least one of Ar601, L601, and R601 may each independently be a π electron-deficient nitrogen-containing C1-C60 cyclic group unsubstituted or substituted with at least one R10a.


In an embodiment, when xe11 in Formula 601 is 2 or more, two or more of Ar601 (s) may be linked via a single bond.


In an embodiment, Ar601 in Formula 601 may be a substituted or unsubstituted anthracene group.


In an embodiment, the electron transport region may include a compound represented by Formula 601-1:




embedded image - Formula 601-1


wherein, in Formula 601-1,

  • X614 may be N or C(R614), X615 may be N or C(R615), X616 may be N or C(R616), at least one of X614 to X616 may be N,
  • L611 to L613 are respectively the same as those described in connection with L601,
  • xe611 to xe613 are respectively the same as those described in connection with xe1,
  • R611 to R613 are respectively the same as those described in connection with R601, and
  • R614 to R616 may each independently be hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C20 alkyl group, a C1-C20 alkoxy group, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a.


In an embodiment, xe1 and xe611 to xe613 in Formulae 601 and 601-1 may each independently be 0, 1, or 2.


The electron transport region may include one of Compounds ET1 to ET45, 2,9-dimethyl-4,7-diphenyl-1,10-phenanthroline (BCP), 4,7-diphenyl-1,10-phenanthroline (Bphen), Alq3, BAlq, TAZ, NTAZ, or any combination thereof:




embedded image - ET1




embedded image - ET2




embedded image - ET3




embedded image - ET4




embedded image - ET5




embedded image - ET6




embedded image - ET7




embedded image - ET8




embedded image - ET9




embedded image - ET10




embedded image - ET11




embedded image - ET12




embedded image - ET13




embedded image - ET14




embedded image - ET15




embedded image - ET16




embedded image - ET17




embedded image - ET18




embedded image - ET19




embedded image - ET20




embedded image - ET21




embedded image - ET22




embedded image - ET23




embedded image - ET24




embedded image - ET25




embedded image - ET26




embedded image - ET27




embedded image - ET28




embedded image - ET29




embedded image - ET30




embedded image - ET31




embedded image - ET32




embedded image - ET33




embedded image - ET34




embedded image - ET35




embedded image - ET36




embedded image - ET37




embedded image - ET38




embedded image - ET39




embedded image - ET40




embedded image - ET41




embedded image - ET42




embedded image - ET43




embedded image - ET44




embedded image - ET45




embedded image - Alq3




embedded image - BAlq




embedded image - TAZ




embedded image - NTAZ


A thickness of the electron transport region may be from about 100 Å to about 5,000 Å, for example, about 160 Å to about 4,000 Å. When the electron transport region includes a buffer layer, a hole blocking layer, an electron control layer, an electron transport layer, or any combination thereof, the thickness of the buffer layer, the hole blocking layer, or the electron control layer may each independently be from about 20 Å to about 1000 Å, for example, about 30 Å to about 300 Å, and the thickness of the electron transport layer may be from about 100 Å to about 1,000 Å, for example, about 150 Å to about 500 Å. When the thickness of the buffer layer, the hole blocking layer, the electron control layer, the electron transport layer, and/or the electron transport region are within these ranges, suitable or satisfactory electron transporting characteristics may be obtained without a substantial increase in driving voltage.


The electron transport region (for example, the electron transport layer in the electron transport region) may further include, in addition to the materials described above, a metal-containing material.


The metal-containing material may include an alkali metal complex, an alkaline earth metal complex, or any combination thereof. A metal ion of the alkali metal complex may be a Li ion, a Na ion, a K ion, a Rb ion, or a Cs ion, and a metal ion of the alkaline earth metal complex may be a Be ion, a Mg ion, a Ca ion, a Sr ion, or a Ba ion. A ligand coordinated with the metal ion of the alkali metal complex or the alkaline earth-metal complex may include a hydroxyquinoline, a hydroxyisoquinoline, a hydroxybenzoquinoline, a hydroxyacridine, a hydroxyphenanthridine, a hydroxyphenyloxazole, a hydroxyphenylthiazole, a hydroxyphenyloxadiazole, a hydroxyphenylthiadiazole, a hydroxyphenylpyridine, a hydroxyphenylbenzimidazole, a hydroxyphenylbenzothiazole, a bipyridine, a phenanthroline, a cyclopentadiene, or any combination thereof.


In an embodiment, the metal-containing material may include a Li complex. The Li complex may include, for example, Compound ET-D1 (LiQ) or ET-D2:




embedded image - ET-D1




embedded image - ET-D2


The electron transport region may include an electron injection layer that facilitates the injection of electrons from the second electrode 150. The electron injection layer may be in direct contact with the second electrode 150.


The electron injection layer may have: i) a single-layered structure consisting of a single layer consisting of a single material, ii) a single-layered structure consisting of a single layer consisting of a plurality of different materials, or iii) a multi-layered structure including a plurality of layers including different materials.


The electron injection layer may include an alkali metal, an alkaline earth metal, a rare earth metal, an alkali metal-containing compound, an alkaline earth metal-containing compound, a rare earth metal-containing compound, an alkali metal complex, an alkaline earth metal complex, a rare earth metal complex, or any combination thereof.


The alkali metal may include Li, Na, K, Rb, Cs, or any combination thereof. The alkaline earth metal may include Mg, Ca, Sr, Ba, or any combination thereof. The rare earth metal may include Sc, Y, Ce, Tb, Yb, Gd, or any combination thereof.


The alkali metal-containing compound, the alkaline earth metal-containing compound, and the rare earth metal-containing compound may include oxides, halides (for example, fluorides, chlorides, bromides, or iodides), or tellurides of the alkali metal, the alkaline earth metal, and the rare earth metal, or any combination thereof.


The alkali metal-containing compound may include alkali metal oxides, such as Li2O, Cs2O, or K2O, alkali metal halides, such as LiF, NaF, CsF, KF, Lil, Nal, Csl, or KI, or any combination thereof. The alkaline earth metal-containing compound may include an alkaline earth metal compound, such as BaO, SrO, CaO, BaxSr1-xO (x is a real number satisfying the condition of 0<x<1), BaxCa1-xO (x is a real number satisfying the condition of 0<x<1), or the like. The rare earth metal-containing compound may include YbF3, ScF3, Sc2O3, Y2O3, Ce2O3, GdF3, TbF3, Ybl3, Scl3, Tbl3, or any combination thereof. In an embodiment, the rare earth metal-containing compound may include lanthanide metal telluride. Examples of the lanthanide metal telluride may include LaTe, CeTe, PrTe, NdTe, PmTe, SmTe, EuTe, GdTe, TbTe, DyTe, HoTe, ErTe, TmTe, YbTe, LuTe, La2Te3, Ce2Te3, Pr2Te3, Nd2Te3, Pm2Te3, Sm2Te3, Eu2Te3, Gd2Tes, Tb2Te3, Dy2Tes, Ho2Te3, Er2Te3, Tm2Tes, Yb2Te3, and Lu2Te3.


The alkali metal complex, the alkaline earth-metal complex, and the rare earth metal complex may include i) one of ions of the alkali metal, the alkaline earth metal, and the rare earth metal and ii), as a ligand bonded to the metal ion, for example, a hydroxyquinoline, a hydroxyisoquinoline, a hydroxybenzoquinoline, a hydroxyacridine, a hydroxyphenanthridine, a hydroxyphenyloxazole, a hydroxyphenylthiazole, a hydroxyphenyloxadiazole, a hydroxyphenylthiadiazole, a hydroxyphenylpyridine, a hydroxyphenyl benzimidazole, a hydroxyphenylbenzothiazole, a bipyridine, a phenanthroline, a cyclopentadiene, or any combination thereof.


The electron injection layer may include (or consist of) an alkali metal, an alkaline earth metal, a rare earth metal, an alkali metal-containing compound, an alkaline earth metal-containing compound, a rare earth metal-containing compound, an alkali metal complex, an alkaline earth metal complex, a rare earth metal complex, or any combination thereof, as described above. In an embodiment, the electron injection layer may further include an organic material (for example, a compound represented by Formula 601).


In an embodiment, the electron injection layer may include (or consist of) i) an alkali metal-containing compound (for example, an alkali metal halide), ii) a) an alkali metal-containing compound (for example, an alkali metal halide); and b) an alkali metal, an alkaline earth metal, a rare earth metal, or any combination thereof. For example, the electron injection layer may be a KI:Yb co-deposited layer, a Rbl:Yb co-deposited layer, a LiF:Yb co-deposited, and/or the like.


When the electron injection layer further includes an organic material, alkali metal, alkaline earth metal, rare earth metal, an alkali metal-containing compound, an alkaline earth metal-containing compound, a rare earth metal-containing compound, alkali metal complex, alkaline earth-metal complex, rare earth metal complex, or any combination thereof may be homogeneously or non-homogeneously dispersed in a matrix including the organic material.


A thickness of the electron injection layer may be in a range of about 1 Å to about 100 Å, and, for example, about 3 Å to about 90 Å. When the thickness of the electron injection layer is within the range described above, suitable or satisfactory electron injection characteristics may be obtained without a substantial increase in driving voltage.


Second Electrode 150

The second electrode 150 may be on the interlayer 130 having such a structure. The second electrode 150 may be a cathode, which is an electron injection electrode, and as the material for the second electrode 150, a metal, an alloy, an electrically conductive compound, or any combination thereof, each having a low work function, may be used.


In an embodiment, the second electrode 150 may include lithium (Li), silver (Ag), magnesium (Mg), aluminum (Al), aluminum-lithium (Al—Li), calcium (Ca), magnesium-indium (Mg—In), magnesium-silver (Mg—Ag), ytterbium (Yb), silver-ytterbium (Ag—Yb), ITO, IZO, or a combination thereof. The second electrode 150 may be a transmissive electrode, a semi-transmissive electrode, or a reflective electrode.


The second electrode 150 may have a single-layered structure or a multi-layered structure including two or more layers.


Capping Layer

A first capping layer may be outside the first electrode 110, and/or a second capping layer may be outside the second electrode 150. In more detail, the light-emitting device 10 may have a structure in which the first capping layer, the first electrode 110, the interlayer 130, and the second electrode 150 are sequentially stacked in this stated order, a structure in which the first electrode 110, the interlayer 130, the second electrode 150, and the second capping layer are sequentially stacked in this stated order, or a structure in which the first capping layer, the first electrode 110, the interlayer 130, the second electrode 150, and the second capping layer are sequentially stacked in this stated order.


Light generated in an emission layer of the interlayer 130 of the light-emitting device 10 may be extracted toward the outside through the first electrode 110, which is a semi-transmissive electrode or a transmissive electrode, and the first capping layer or light generated in an emission layer of the interlayer 130 of the light-emitting device 10 may be extracted toward the outside through the second electrode 150, which is a semi-transmissive electrode or a transmissive electrode, and the second capping layer.


The first capping layer and the second capping layer may increase external emission efficiency according to the principle of constructive interference. Accordingly, the light extraction efficiency of the light-emitting device 10 is increased, so that the emission efficiency of the light-emitting device 10 may be improved.


Each of the first capping layer and second capping layer may include a material having a refractive index (at a wavelength of 589 nm) of 1.6 or more.


The first capping layer and the second capping layer may each independently be an organic capping layer including an organic material, an inorganic capping layer including an inorganic material, or an organic-inorganic composite capping layer including an organic material and an inorganic material.


At least one of the first capping layer and the second capping layer may each independently include carbocyclic compounds, heterocyclic compounds, amine group-containing compounds, porphyrin derivatives, phthalocyanine derivatives, naphthalocyanine derivatives, alkali metal complexes, alkaline earth metal complexes, or any combination thereof. The carbocyclic compound, the heterocyclic compound, and the amine group-containing compound may be optionally substituted with a substituent containing O, N, S, Se, Si, F, Cl, Br, I, or any combination thereof. In an embodiment, at least one of the first capping layer and the second capping layer may each independently include an amine group-containing compound.


In an embodiment, at least one of the first capping layer and the second capping layer may each independently include a compound represented by Formula 201, a compound represented by Formula 202, or any combination thereof.


In an embodiment, at least one of the first capping layer and the second capping layer may each independently include one of Compounds HT28 to HT33, one of Compounds CP1 to CP6, β-NPB, or any combination thereof:




embedded image - CP1




embedded image - CP2




embedded image - CP3




embedded image - CP4




embedded image - CP5




embedded image - CP6




embedded image - β-NPB


Film

The organometallic compound represented by Formula 1-1 or 1-2 may be included in various suitable films. Accordingly, according to one or more embodiments, a film including the organometallic compound represented by Formula 1-1 or 1-2 may be provided. The film may be, for example, an optical member (e.g., a light control means such as, for example, a color filter, a color conversion member, a capping layer, a light extraction efficiency enhancement layer, a selective light absorbing layer, a polarizing layer, a quantum dot-containing layer, and/or like), a light-blocking member (for example, a light reflective layer, a light absorbing layer, and/or the like), and/or a protective member (for example, an insulating layer, a dielectric layer, and/or the like).


Electronic Apparatus

The light-emitting device may be included in various suitable electronic apparatuses. In an embodiment, the electronic apparatus including the light-emitting device may be a light-emitting apparatus, an authentication apparatus, and/or the like.


The electronic apparatus (for example, light-emitting apparatus) may further include, in addition to the light-emitting device, i) a color filter, ii) a color conversion layer, or iii) a color filter and a color conversion layer. The color filter and/or the color conversion layer may be in at least one traveling direction of light emitted from the light-emitting device. For example, the light emitted from the light-emitting device may be blue light or white light. The light-emitting device may be the same as described above. In an embodiment, the color conversion layer may include quantum dots. The quantum dot may be, for example, a quantum dot as described herein.


The electronic apparatus may include a first substrate. The first substrate may include a plurality of subpixel areas, the color filter may include a plurality of color filter areas respectively corresponding to the subpixel areas, and the color conversion layer may include a plurality of color conversion areas respectively corresponding to the subpixel areas.


A pixel-defining film may be located among the subpixel areas to define each of the subpixel areas.


The color filter may further include a plurality of color filter areas and light-shielding patterns located among the color filter areas, and the color conversion layer may include a plurality of color conversion areas and light-shielding patterns located among the color conversion areas.


The color filter areas (or the color conversion areas) may include a first area that emits a first color light, a second area that emits a second color light, and/or a third area that emits a third color light, and the first color light, the second color light, and/or the third color light may have different maximum emission wavelengths from one another. In an embodiment, the first color light may be red light, the second color light may be green light, and the third color light may be blue light. In an embodiment, the color filter areas (or the color conversion areas) may include quantum dots. In more detail, the first area may include a red quantum dot, the second area may include a green quantum dot, and the third area may not include a quantum dot. The quantum dot is the same as described in the present specification. The first area, the second area, and/or the third area may each further include a scatterer (e.g., a light scatterer).


In an embodiment, the light-emitting device may emit a first light, the first area may absorb the first light to emit a first first-color light, the second area may absorb the first light to emit a second first-color light, and the third area may absorb the first light to emit a third first-color light. In this regard, the first first-color light, the second first-color light, and the third first-color light may have different maximum emission wavelengths. In more detail, the first light may be blue light, the first first-color light may be red light, the second first-color light may be green light, and the third first-color light may be blue light.


The electronic apparatus may further include a thin-film transistor in addition to the light-emitting device as described above. The thin-film transistor may include a source electrode, a drain electrode, and an activation layer, wherein any one of the source electrode or the drain electrode may be electrically connected to any one of the first electrode or the second electrode of the light-emitting device.


The thin-film transistor may further include a gate electrode, a gate insulating film, etc.


The activation layer may include crystalline silicon, amorphous silicon, organic semiconductor, oxide semiconductor, and/or the like.


The electronic apparatus may further include a sealing portion for sealing the light-emitting device. The sealing portion and/or the color conversion layer may be between the color filter and the light-emitting device. The sealing portion allows light from the light-emitting device to be extracted to the outside, while concurrently (e.g., simultaneously) preventing or reducing penetration of ambient air and/or moisture into the light-emitting device. The sealing portion may be a sealing substrate including a transparent glass substrate and/or a plastic substrate. The sealing portion may be a thin-film encapsulation layer including at least one layer of an organic layer and/or an inorganic layer. When the sealing portion is a thin film encapsulation layer, the electronic apparatus may be flexible.


Various suitable functional layers may be additionally on the sealing portion, in addition to the color filter and/or the color conversion layer, according to the use of the electronic apparatus. The functional layers may include a touch screen layer, a polarizing layer, and/or the like. The touch screen layer may be a pressure-sensitive touch screen layer, a capacitive touch screen layer, and/or an infrared touch screen layer.


The authentication apparatus may further include, in addition to the light-emitting device, a biometric information collector. The authentication apparatus may be, for example, a biometric authentication apparatus that authenticates an individual by using biometric information of a living body (for example, fingertips, pupils, etc.).


The electronic apparatus may be applied to various suitable displays, light sources, lighting, personal computers (for example, a mobile personal computer), mobile phones, digital cameras, electronic diaries, electronic dictionaries, electronic game machines, medical instruments (for example, electronic thermometers, sphygmomanometers, blood glucose meters, pulse measurement devices, pulse wave measurement devices, electrocardiogram displays, ultrasonic diagnostic devices, and/or endoscope displays), fish finders, various suitable measuring instruments, meters (for example, meters for a vehicle, an aircraft, and/or a vessel), projectors, and/or the like.


Description of FIGS. 2 and 3


FIG. 2 is a cross-sectional view of a light-emitting apparatus according to an embodiment of the disclosure.


The light-emitting apparatus of FIG. 2 includes a substrate 100, a thin-film transistor (TFT), a light-emitting device, and an encapsulation portion 300 that seals the light-emitting device.


The substrate 100 may be a flexible substrate, a glass substrate, and/or a metal substrate. A buffer layer 210 may be on the substrate 100. The buffer layer 210 may prevent or reduce penetration of impurities through the substrate 100 and may provide a flat surface on the substrate 100.


A TFT may be on the buffer layer 210. The TFT may include an activation layer 220, a gate electrode 240, a source electrode 260, and a drain electrode 270.


The activation layer 220 may include an inorganic semiconductor such as silicon and/or polysilicon, an organic semiconductor, and/or an oxide semiconductor, and may include a source region, a drain region, and a channel region.


A gate insulating film 230 for insulating the activation layer 220 from the gate electrode 240 may be on the activation layer 220, and the gate electrode 240 may be on the gate insulating film 230.


An interlayer insulating film 250 is on the gate electrode 240. The interlayer insulating film 250 may be between the gate electrode 240 and the source electrode 260 to insulate the gate electrode 240 from the source electrode 260 and between the gate electrode 240 and the drain electrode 270 to insulate the gate electrode 240 from the drain electrode 270.


The source electrode 260 and the drain electrode 270 may be on the interlayer insulating film 250. The interlayer insulating film 250 and the gate insulating film 230 may expose the source region and the drain region of the activation layer 220, and the source electrode 260 and the drain electrode 270 may be in contact (e.g., physical contact) with the exposed portions of the source region and the drain region, respectively, of the activation layer 220.


The TFT is electrically connected to a light-emitting device to drive the light-emitting device, and is covered by a passivation layer 280. The passivation layer 280 may include an inorganic insulating film, an organic insulating film, or a combination thereof. A light-emitting device is provided on the passivation layer 280. The light-emitting device may include a first electrode 110, an interlayer 130, and a second electrode 150.


The first electrode 110 may be on the passivation layer 280. The passivation layer 280 does not completely cover the drain electrode 270 and exposes a portion of the drain electrode 270, and the first electrode 110 is connected to the exposed portion of the drain electrode 270.


A pixel-defining layer 290 containing an insulating material may be on the first electrode 110. The pixel-defining layer 290 exposes a region of the first electrode 110, and an interlayer 130 may be in the exposed region of the first electrode 110. The pixel-defining layer 290 may be a polyimide and/or polyacrylic organic film. In some embodiments, at least some layers of the interlayer 130 may extend beyond the upper portion of the pixel-defining layer 290 in the form of a common layer.


The second electrode 150 may be on the interlayer 130, and a capping layer 170 may be additionally on the second electrode 150. The capping layer 170 may cover the second electrode 150.


The encapsulation portion 300 may be on the capping layer 170. The encapsulation portion 300 may be on a light-emitting device to protect the light-emitting device from moisture and/or oxygen. The encapsulation portion 300 may include: an inorganic film including silicon nitride (SiNx), silicon oxide (SiOx), indium tin oxide, indium zinc oxide, or any combination thereof; an organic film including polyethylene terephthalate, polyethylene naphthalate, polycarbonate, polyimide, polyethylene sulfonate, polyoxymethylene, polyarylate, hexamethyldisiloxane, an acrylic resin (for example, polymethyl methacrylate, polyacrylic acid, and/or the like), an epoxy-based resin (for example, aliphatic glycidyl ether (AGE), and/or the like), or a combination thereof; or a combination of the inorganic film and the organic film.



FIG. 3 is a cross-sectional view of a light-emitting apparatus according to an embodiment of the disclosure.


The light-emitting apparatus of FIG. 3 is substantially the same as the light-emitting apparatus of FIG. 2, except that a light-shielding pattern 500 and a functional region 400 are additionally on the encapsulation portion 300. The functional region 400 may be a combination of i) a color filter area, ii) a color conversion area, or iii) a combination of the color filter area and the color conversion area. In an embodiment, the light-emitting device included in the light-emitting apparatus of FIG. 3 may be a tandem light-emitting device.


Manufacture Method

Respective layers included in the hole transport region, the emission layer, and respective layers included in the electron transport region may be formed in a certain region by using one or more suitable methods selected from vacuum deposition, spin coating, casting, Langmuir-Blodgett (LB) deposition, ink-jet printing, laser-printing, and laser-induced thermal imaging.


When layers constituting the hole transport region, an emission layer, and layers constituting the electron transport region are formed by vacuum deposition, the deposition may be performed at a deposition temperature of about 100° C. to about 500° C., a vacuum degree of about 10-8 torr to about 10-3 torr, and a deposition speed of about 0.01 Å/sec to about 100 Å/sec, depending on a material to be included in a layer to be formed and the structure of a layer to be formed.


Definition of Terms

The term “C3-C60 carbocyclic group,” as used herein, refers to a cyclic group consisting of carbon only as a ring-forming atom and having three to sixty carbon atoms, and the term “C1-C60 heterocyclic group,” as used herein, refers to a cyclic group that has one to sixty carbon atoms and further has, in addition to carbon, a heteroatom as a ring-forming atom. The C3-C60 carbocyclic group and the C1-C60 heterocyclic group may each be a monocyclic group consisting of one ring or a polycyclic group in which two or more rings are condensed together with each other. In an embodiment, the C1-C60 heterocyclic group has 3 to 61 ring-forming atoms.


The term “cyclic group,” as used herein, may include the C3-C60 carbocyclic group and the C1-C60 heterocyclic group.


The term “π electron-rich C3-C60 cyclic group,” as used herein, refers to a cyclic group that has three to sixty carbon atoms and does not include *—N═*’ as a ring-forming moiety, and the term “π electron-deficient nitrogen-containing C1-C60 cyclic group,” as used herein, refers to a heterocyclic group that has one to sixty carbon atoms and includes *—N═*’ as a ring-forming moiety.


In an embodiment,

  • the C3-C60 carbocyclic group may be i) group T1 or ii) a condensed cyclic group in which two or more groups T1 are condensed together with each other (for example, a cyclopentadiene group, an adamantane group, a norbornane group, a benzene group, a pentalene group, a naphthalene group, an azulene group, an indacene group, an acenaphthylene group, a phenalene group, a phenanthrene group, an anthracene group, a fluoranthene group, a triphenylene group, a pyrene group, a chrysene group, a perylene group, a pentaphene group, a heptalene group, a naphthacene group, a picene group, a hexacene group, a pentacene group, a rubicene group, a coronene group, an ovalene group, an indene group, a fluorene group, a spiro-bifluorene group, a benzofluorene group, an indenophenanthrene group, or an indenoanthracene group),
  • the C1-C60 heterocyclic group may be i) group T2, ii) a condensed cyclic group in which two or more groups T2 are condensed together with each other, or iii) a condensed cyclic group in which at least one group T2 and at least one group T1 are condensed together with each other (for example, a pyrrole group, a thiophene group, a furan group, an indole group, a benzoindole group, a naphthoindole group, an isoindole group, a benzoisoindole group, a naphthoisoindole group, a benzosilole group, a benzothiophene group, a benzofuran group, a carbazole group, a dibenzosilole group, a dibenzothiophene group, a dibenzofuran group, an indenocarbazole group, an indolocarbazole group, a benzofurocarbazole group, a benzothienocarbazole group, a benzosilolocarbazole group, a benzoindolocarbazole group, a benzocarbazole group, a benzonaphthofuran group, a benzonaphthothiophene group, a benzonaphthosilole group, a benzofurodibenzofuran group, a benzofurodibenzothiophene group, a benzothienodibenzothiophene group, a pyrazole group, an imidazole group, a triazole group, an oxazole group, an isoxazole group, an oxadiazole group, a thiazole group, an isothiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a benzoxazole group, a benzoisoxazole group, a benzothiazole group, a benzoisothiazole group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a benzoquinoline group, a benzoisoquinoline group, a quinoxaline group, a benzoquinoxaline group, a quinazoline group, a benzoquinazoline group, a phenanthroline group, a cinnoline group, a phthalazine group, a naphthyridine group, an imidazopyridine group, an imidazopyrimidine group, an imidazotriazine group, an imidazopyrazine group, an imidazopyridazine group, an azacarbazole group, an azafluorene group, an azadibenzosilole group, an azadibenzothiophene group, an azadibenzofuran group, etc.),
  • the π electron-rich C3-C60 cyclic group may be i) group T1, ii) a condensed cyclic group in which two or more groups T1 are condensed together with each other, iii) group T3, iv) a condensed cyclic group in which two or more groups T3 are condensed together with each other, or v) a condensed cyclic group in which at least one group T3 and at least one group T1 are condensed together with each other (for example, the C3-C60 carbocyclic group, a 1H-pyrrole group, a silole group, a borole group, a 2H-pyrrole group, a 3H-pyrrole group, a thiophene group, a furan group, an indole group, a benzoindole group, a naphthoindole group, an isoindole group, a benzoisoindole group, a naphthoisoindole group, a benzosilole group, a benzothiophene group, a benzofuran group, a carbazole group, a dibenzosilole group, a dibenzothiophene group, a dibenzofuran group, an indenocarbazole group, an indolocarbazole group, a benzofurocarbazole group, a benzothienocarbazole group, a benzosilolocarbazole group, a benzoindolocarbazole group, a benzocarbazole group, a benzonaphthofuran group, a benzonaphthothiophene group, a benzonaphthosilole group, a benzofurodibenzofuran group, a benzofurodibenzothiophene group, a benzothienodibenzothiophene group, etc.),
  • the π electron-deficient nitrogen-containing C1-C60 cyclic group may be i) group T4, ii) a condensed cyclic group in which two or more group T4 are condensed together with each other, iii) a condensed cyclic group in which at least one group T4 and at least one group T1 are condensed together with each other, iv) a condensed cyclic group in which at least one group T4 and at least one group T3 are condensed together with each other, or v) a condensed cyclic group in which at least one group T4, at least one group T1, and at least one group T3 are condensed together with one another (for example, a pyrazole group, an imidazole group, a triazole group, an oxazole group, an isoxazole group, an oxadiazole group, a thiazole group, an isothiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a benzoxazole group, a benzoisoxazole group, a benzothiazole group, a benzoisothiazole group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a benzoquinoline group, a benzoisoquinoline group, a quinoxaline group, a benzoquinoxaline group, a quinazoline group, a benzoquinazoline group, a phenanthroline group, a cinnoline group, a phthalazine group, a naphthyridine group, an imidazopyridine group, an imidazopyrimidine group, an imidazotriazine group, an imidazopyrazine group, an imidazopyridazine group, an azacarbazole group, an azafluorene group, an azadibenzosilole group, an azadibenzothiophene group, an azadibenzofuran group, etc.),
  • group T1 may be a cyclopropane group, a cyclobutane group, a cyclopentane group, a cyclohexane group, a cycloheptane group, a cyclooctane group, a cyclobutene group, a cyclopentene group, a cyclopentadiene group, a cyclohexene group, a cyclohexadiene group, a cycloheptene group, an adamantane group, a norbornane (or a bicyclo[2.2.1]heptane) group, a norbornene group, a bicyclo[1.1.1]pentane group, a bicyclo[2.1.1]hexane group, a bicyclo[2.2.2]octane group, or a benzene group,
  • group T2 may be a furan group, a thiophene group, a 1H-pyrrole group, a silole group, a borole group, a 2H-pyrrole group, a 3H-pyrrole group, an imidazole group, a pyrazole group, a triazole group, a tetrazole group, an oxazole group, an isoxazole group, an oxadiazole group, a thiazole group, an isothiazole group, a thiadiazole group, an azasilole group, an azaborole group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a tetrazine group, a pyrrolidine group, an imidazolidine group, a dihydropyrrole group, a piperidine group, a tetrahydropyridine group, a dihydropyridine group, a hexahydropyrimidine group, a tetrahydropyrimidine group, a dihydropyrimidine group, a piperazine group, a tetrahydropyrazine group, a dihydropyrazine group, a tetrahydropyridazine group, or a dihydropyridazine group,
  • group T3 may be a furan group, a thiophene group, a 1H-pyrrole group, a silole group, or a borole group, and
  • group T4 may be a 2H-pyrrole group, a 3H-pyrrole group, an imidazole group, a pyrazole group, a triazole group, a tetrazole group, an oxazole group, an isoxazole group, an oxadiazole group, a thiazole group, an isothiazole group, a thiadiazole group, an azasilole group, an azaborole group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, or a tetrazine group.


The term “cyclic group”, “C3-C60 carbocyclic group”, “C1-C60 heterocyclic group”, “π electron-rich C3-C60 cyclic group”, or “π electron-deficient nitrogen-containing C1-C60 cyclic group,” as used herein, refers to a group condensed to any cyclic group or a polyvalent group (for example, a divalent group, a trivalent group, a tetravalent group, etc.), depending on the structure of a formula in connection with which the terms are used. In an embodiment, “a benzene group” may be a benzo group, a phenyl group, a phenylene group, or the like, which may be easily understood by one of ordinary skill in the art according to the structure of a formula including the “benzene group.”


Examples of the monovalent C3-C60 carbocyclic group and the monovalent C1-C60 heterocyclic group may include a C3-C10 cycloalkyl group, a C1-C10 heterocycloalkyl group, a C3-C10 cycloalkenyl group, a C1-C10 heterocycloalkenyl group, a C6-C60 aryl group, a C1-C60 heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group, and examples of the divalent C3-C60 carbocyclic group and the monovalent C1-C60 heterocyclic group may include a C3-C10 cycloalkylene group, a C1-C10 heterocycloalkylene group, a C3-C10 cycloalkenylene group, a C1-C10 heterocycloalkenylene group, a C6-C60 arylene group, a C1-C60 heteroarylene group, a divalent non-aromatic condensed polycyclic group, and a substituted or unsubstituted divalent non-aromatic condensed heteropolycyclic group.


The term “C1-C60 alkyl group,” as used herein, refers to a linear or branched aliphatic hydrocarbon monovalent group that has one to sixty carbon atoms, and examples thereof include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, a sec-butyl group, an isobutyl group, a tert-butyl group, an n-pentyl group, a tert-pentyl group, a neopentyl group, an isopentyl group, a sec-pentyl group, a 3-pentyl group, a sec-isopentyl group, an n-hexyl group, an isohexyl group, a sec-hexyl group, a tert-hexyl group, an n-heptyl group, an isoheptyl group, a sec-heptyl group, a tert-heptyl group, an n-octyl group, an isooctyl group, a sec-octyl group, a tert-octyl group, an n-nonyl group, an isononyl group, a sec-nonyl group, a tert-nonyl group, an n-decyl group, an isodecyl group, a sec-decyl group, and a tert-decyl group. The term “C1-C60 alkylene group,” as used herein, refers to a divalent group having substantially the same structure as the C1-C60 alkyl group.


The term “C2-C60 alkenyl group,” as used herein, refers to a monovalent hydrocarbon group having at least one carbon-carbon double bond at a main chain (e.g., in the middle) or at a terminal end (e.g., the terminus) of the C2-C60 alkyl group, and examples thereof include an ethenyl group, a propenyl group, and a butenyl group. The term “C2-C60 alkenylene group,” as used herein, refers to a divalent group having substantially the same structure as the C2-C60 alkenyl group.


The term “C2-C60 alkynyl group,” as used herein, refers to a monovalent hydrocarbon group having at least one carbon-carbon triple bond at a main chain (e.g., in the middle) or at a terminal end (e.g., the terminus) of the C2-C60 alkyl group, and examples thereof include an ethynyl group and a propynyl group. The term “C2-C60 alkynylene group,” as used herein, refers to a divalent group having substantially the same structure as the C2-C60 alkynyl group.


The term “C1-C60 alkoxy group,” as used herein, refers to a monovalent group represented by -OA101 (wherein A101 is the C1-C60 alkyl group), and examples thereof include a methoxy group, an ethoxy group, and an isopropyloxy group.


The term “C3-C10 cycloalkyl group,” as used herein, refers to a monovalent saturated hydrocarbon cyclic group having 3 to 10 carbon atoms, and examples thereof include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group (or a bicyclo[2.2.1]heptyl group), a bicyclo[1.1.1]pentyl group, a bicyclo[2.1.1]hexyl group, and a bicyclo[2.2.2]octyl group. The term “C3-C10 cycloalkylene group,” as used herein, refers to a divalent group having substantially the same structure as the C3-C10 cycloalkyl group.


The term “C1-C10 heterocycloalkyl group,” as used herein, refers to a monovalent cyclic group that further includes, in addition to a carbon atom, at least one heteroatom as a ring-forming atom and has 1 to 10 carbon atoms, and examples thereof include a 1,2,3,4-oxatriazolidinyl group, a tetrahydrofuranyl group, and a tetrahydrothiophenyl group. The term “C1-C10 heterocycloalkylene group,” as used herein, refers to a divalent group having substantially the same structure as the C1-C10 heterocycloalkyl group.


The term “C3-C10 cycloalkenyl group,” as used herein, refers to a monovalent cyclic group that has three to ten carbon atoms and at least one carbon-carbon double bond in the ring thereof and no aromaticity (e.g., is not aromatic), and examples thereof include a cyclopentenyl group, a cyclohexenyl group, and a cycloheptenyl group. The term “C3-C10 cycloalkenylene group,” as used herein, refers to a divalent group having substantially the same structure as the C3-C10 cycloalkenyl group.


The term “C1-C10 heterocycloalkenyl group,” as used herein, refers to a monovalent cyclic group that has, in addition to a carbon atom, at least one heteroatom as a ring-forming atom, 1 to 10 carbon atoms, and at least one carbon-carbon double bond in the cyclic structure thereof. Examples of the C1-C10 heterocycloalkenyl group include a 4,5-dihydro-1,2,3,4-oxatriazolyl group, a 2,3-dihydrofuranyl group, and a 2,3-dihydrothiophenyl group. The term “C1-C10 heterocycloalkenylene group,” as used herein, refers to a divalent group having substantially the same structure as the C1-C10 heterocycloalkenyl group.


The term “C6-C60 aryl group,” as used herein, refers to a monovalent group having a carbocyclic aromatic system having six to sixty carbon atoms, and the term “C6-C60 arylene group,” as used herein, refers to a divalent group having a carbocyclic aromatic system having six to sixty carbon atoms. Examples of the C6-C60 aryl group include a phenyl group, a pentalenyl group, a naphthyl group, an azulenyl group, an indacenyl group, an acenaphthyl group, a phenalenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a perylenyl group, a pentaphenyl group, a heptalenyl group, a naphthacenyl group, a picenyl group, a hexacenyl group, a pentacenyl group, a rubicenyl group, a coronenyl group, and an ovalenyl group. When the C6-C60 aryl group and the C6-C60 arylene group each include two or more rings, the rings may be condensed together with each other.


The term “C1-C60 heteroaryl group,” as used herein, refers to a monovalent group having a heterocyclic aromatic system that has, in addition to a carbon atom, at least one heteroatom as a ring-forming atom, and 1 to 60 carbon atoms. The term “C1-C60 heteroarylene group,” as used herein, refers to a divalent group having a heterocyclic aromatic system that has, in addition to a carbon atom, at least one heteroatom as a ring-forming atom, and 1 to 60 carbon atoms. Examples of the C1-C60 heteroaryl group include a pyridinyl group, a pyrimidinyl group, a pyrazinyl group, a pyridazinyl group, a triazinyl group, a quinolinyl group, a benzoquinolinyl group, an isoquinolinyl group, a benzoisoquinolinyl group, a quinoxalinyl group, a benzoquinoxalinyl group, a quinazolinyl group, a benzoquinazolinyl group, a cinnolinyl group, a phenanthrolinyl group, a phthalazinyl group, and a naphthyridinyl group. When the C1-C60 heteroaryl group and the C1-C60 heteroarylene group each include two or more rings, the rings may be condensed together with each other.


The term “monovalent non-aromatic condensed polycyclic group,” as used herein, refers to a monovalent group having two or more rings condensed to each other, only carbon atoms (for example, having 8 to 60 carbon atoms) as ring-forming atoms, and non-aromaticity in its molecular structure when considered as a whole (e.g., is not aromatic when considered as a whole). Examples of the monovalent non-aromatic condensed polycyclic group include an indenyl group, a fluorenyl group, a spiro-bifluorenyl group, a benzofluorenyl group, an indenophenanthrenyl group, and an indeno anthracenyl group. The term “divalent non-aromatic condensed polycyclic group,” as used herein, refers to a divalent group having substantially the same structure as a monovalent non-aromatic condensed polycyclic group.


The term “monovalent non-aromatic condensed heteropolycyclic group,” as used herein, refers to a monovalent group having two or more rings condensed to each other, at least one heteroatom other than carbon atoms (for example, having 1 to 60 carbon atoms), as a ring-forming atom, and non-aromaticity in its molecular structure when considered as a whole (e.g., is not aromatic when considered as a whole). Examples of the monovalent non-aromatic condensed heteropolycyclic group include a pyrrolyl group, a thiophenyl group, a furanyl group, an indolyl group, a benzoindolyl group, a naphthoindolyl group, an isoindolyl group, a benzoisoindolyl group, a naphthoisoindolyl group, a benzosilolyl group, a benzothiophenyl group, a benzofuranyl group, a carbazolyl group, a dibenzosilolyl group, a dibenzothiophenyl group, a dibenzofuranyl group, an azacarbazolyl group, an azafluorenyl group, an azadibenzosilolyl group, an azadibenzothiophenyl group, an azadibenzofuranyl group, a pyrazolyl group, an imidazolyl group, a triazolyl group, a tetrazolyl group, an oxazolyl group, an isoxazolyl group, a thiazolyl group, an isothiazolyl group, an oxadiazolyl group, a thiadiazolyl group, a benzopyrazolyl group, a benzimidazolyl group, a benzoxazolyl group, a benzothiazolyl group, a benzoxadiazolyl group, a benzothiadiazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an imidazotriazinyl group, an imidazopyrazinyl group, an imidazopyridazinyl group, an indeno carbazolyl group, an indolocarbazolyl group, a benzofurocarbazolyl group, a benzothienocarbazolyl group, a benzosilolocarbazolyl group, a benzoindolocarbazolyl group, a benzocarbazolyl group, a benzonaphthofuranyl group, a benzonaphthothiophenyl group, a benzonaphtho silolyl group, a benzofurodibenzofuranyl group, a benzofurodibenzothiophenyl group, and a benzothienodibenzothiophenyl group. The term “divalent non-aromatic condensed heteropolycyclic group,” as used herein, refers to a divalent group having substantially the same structure as a monovalent non-aromatic condensed heteropolycyclic group.


The term “C6-C60 aryloxy group,” as used herein, indicates -OA102 (wherein A102 is the C6-C60 aryl group), and the term “C6-C60 arylthio group,” as used herein, indicates -SA103 (wherein A103 is the C6-C60 aryl group).


The term “C7-C60 aryl alkyl group,” used herein, refers to -A104A105 (where A104 may be a C1-C54 alkylene group, and A105 may be a C6-C59 aryl group), and the term “C2-C60 heteroaryl alkyl group,” as used herein, refers to -A106A107 (where A106 may be a C1-C59 alkylene group, and A107 may be a C1-C59 heteroaryl group).


R10a may be:

  • deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, or a nitro group;
  • a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, or a C1-C60 alkoxy group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C3-C60 carbocyclic group, a C1-C60 heterocyclic group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C7-C60 aryl alkyl group, a C2-C60 heteroaryl alkyl group, —Si(Q11)(Q12)(Q13), —N(Q11)(Q12), —B(Q11)(Q12), —C(═O)(Q11), —S(═O)2(Q11), —P(═O)(Q11)(Q12), or any combination thereof;
  • a C3-C60 carbocyclic group, a C1-C60 heterocyclic group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C7-C60 aryl alkyl group, or a C2-C60 heteroaryl alkyl group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a C3-C60 carbocyclic group, a C1-C60 heterocyclic group, a C6-C60 aryloxy group, a C6-C60 arylthio group, a C7-C60 aryl alkyl group, a C2-C60 heteroaryl alkyl group, —Si(Q21)(Q22)(Q23), —N(Q21)(Q22), —B(Q21)(Q22), —C(═O)(Q21), —S(═O)2(Q21), —P(═O)(Q21)(Q22), or any combination thereof; or
  • —Si(Q31)(Q32)(Q33), —N(Q31)(Q32), —B(Q31)(Q32), —C(═O)(Q31), —S(═O)2(Q31), or —P(═O)(Q31)(Q32).


Q1 to Q3, Q11 to Q13, Q21 to Q23, and Q31 to Q33 used herein may each independently be: hydrogen; deuterium; —F; —Cl; —Br; —I; a hydroxyl group; a cyano group; a nitro group; a C1-C60 alkyl group; a C2-C60 alkenyl group; a C2-C60 alkynyl group; a C1-C60 alkoxy group; a C3-C60 carbocyclic group or a C1-C60 heterocyclic group, each unsubstituted or substituted with deuterium, —F, a cyano group, a C1-C60 alkyl group, a C1-C60 alkoxy group, a phenyl group, a biphenyl group, or any combination thereof; a C7-C60 aryl alkyl group; or a C2-C60 heteroaryl alkyl group.


The term “hetero atom,” as used herein, refers to any atom other than a carbon atom. Examples of the heteroatom include O, S, N, P, Si, B, Ge, Se, or any combination thereof.


The term “the third-row transition metal,” as used herein, includes hafnium (Hf), tantalum (Ta), tungsten (W), rhenium (Re), osmium (Os), iridium (Ir), platinum (Pt), gold (Au), and the like.


“Ph,” as used herein, refers to a phenyl group, “Me,” as used herein, refers to a methyl group, “Et,” as used herein, refers to an ethyl group, “tert-Bu” or “But,” as used herein, refers to a tert-butyl group, and “OMe,” as used herein, refers to a methoxy group.


The term “biphenyl group,” as used herein, refers to “a phenyl group substituted with a phenyl group.” In other words, the “biphenyl group” is a substituted phenyl group having a C6-C60 aryl group as a substituent.


The term “terphenyl group,” as used herein, refers to “a phenyl group substituted with a biphenyl group”. The “terphenyl group” is a substituted phenyl group having, as a substituent, a C6-C60 aryl group substituted with a C6-C60 aryl group.


* and *’, as used herein, unless defined otherwise, each refer to a binding site to a neighboring atom in a corresponding formula or moiety.


Hereinafter, compounds according to embodiments and light-emitting devices according to embodiments will be described in more detail with reference to the following synthesis examples and examples. The wording “B was used instead of A” used in describing Synthesis Examples means that an identical molar equivalent of B was used in place of A.


EXAMPLES
Synthesis Example 1



embedded image


Synthesis of Intermediate Compound 1-A

2-chlorobenzimidazole (1.0 eq) and 2-bromoaniline (1.1 eq) were dissolved in N-methyl-2-pyrrolidine (2.0 M) at room temperature, and then methanesulfonic acid (1.1 eq) was slowly added thereto for 0.5 hours. The resultant reaction mixture was heated at 100° C., and then stirred until a starting material disappeared completely. The resultant reaction mixture was cooled at room temperature, diluted with distilled water, and then neutralized with a 30 w-% sodium hydroxide aqueous solution. The product precipitated as a solid was obtained through filtration, washed with water, and then dried under vacuum, to thereby obtain Intermediate Compound 1-A. (yield: 90%)


Synthesis of Intermediate Compound 1-B

Intermediate Compound 1-A (1.0 eq), cesium carbonate (1.3 eq), and copper(II) bromide (2.0 mol%) were dissolved in dimethyl formamide (1.0 M), and then stirred for 24 hours at 130° C. The resultant reaction mixture was cooled at room temperature and then diluted with water. The product precipitated as a solid was obtained through filtration, washed with water, and then dried in a vacuum condition, to thereby obtain Intermediate Compound 1-B. (yield: 93%)


Synthesis of Intermediate Compound 1-C

Intermediate Compound 1-B (1.0 eq), 1-bromo-3-iodobenzene (1.5 eq), Pd2(dba)3 (0.2 eq), 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (Sphos) (0.4 eq), and K3PO4 (2.0 eq) were dissolved in toluene (0.5 M), and then stirred for 12 hours at 120° C. The resultant reaction mixture was cooled at room temperature, and then subjected to an extraction process three times using water to obtain an organic layer. The organic layer thus obtained was dried using magnesium sulfate and concentrated, and column chromatography was used to synthesize Intermediate Compound 1-C (yield: 75%).


Synthesis of Intermediate Compound 1-E

Intermediate Compound 1-C (1.0 eq), 1-D (1.2 eq), copper(I) iodide (0.01 eq), K2CO3 (2.0 eq), and L-Proline (0.02 eq) were dissolved in DMSO (0.1 M), and then stirred for 24 hours at 130° C. The resultant reaction mixture was cooled at room temperature, and then subjected to an extraction process three times using water to obtain an organic layer. The organic layer thus obtained was dried by using magnesium sulfate and concentrated, and column chromatography was used to obtain Intermediate Compound 1-E (yield: 68%).


Synthesis of Compound 1

Intermediate Compound 1-E (1.0 eq) and K2PtCl2 (1.2 eq) were dissolved in 2-ethoxyethanol (0.05 M) and then stirred for 24 hours at 120° C. The resultant reaction mixture was cooled at room temperature, and an extraction process was performed thereon three times by using dichloromethane and water, to thereby obtain an organic layer. The organic layer thus obtained was dried by using magnesium sulfate and concentrated, and column chromatography was used to obtain Compound 1 (yield: 24%).


Synthesis Example 2



embedded image


Synthesis of Intermediate Compound 2-E

Intermediate Compound 2-E (yield: 66%) was synthesized in substantially the same manner as used to synthesize Intermediate Compound 1-E, except that Intermediate Compound 2-D was used instead of Intermediate Compound 1-D.


Synthesis of Compound 2

Compound 2 (yield: 21%) was synthesized in substantially the same manner as used to synthesize Compound 1, except that Intermediate Compound 2-E was used instead of Intermediate Compound 1-E.


Synthesis Example 3



embedded image


Synthesis of Intermediate Compound 3-D

Intermediate Compound 3-D (yield: 53%) was synthesized in substantially the same manner as used to synthesize Intermediate Compound 1-C, except that 3-bromophenol was used instead of 1-bromo-3-iodobenzene.


Synthesis of Intermediate Compound 3-E

Intermediate Compound 3-E (yield: 62%) was synthesized in substantially the same manner as used to synthesize Intermediate Compound 1-E, except that Intermediate Compound 3-D was used instead of Intermediate Compound 1-D.


Synthesis of Compound 51

Compound 51 (yield: 31%) was synthesized in substantially the same manner as used to synthesize Compound 1, except that Intermediate Compound 3-E was used instead of Intermediate Compound 1-E.


Synthesis Example 4



embedded image


Synthesis of Intermediate Compound 4-C

Intermediate Compound 4-C (yield: 67%) was synthesized in substantially the same manner as used to synthesize Intermediate Compound 1-C, except that 1,3-dibromo-5-(tert-butyl)benzene was used instead of 1-bromo-3-iodobenzene.


Synthesis of Intermediate Compound 4-E

Intermediate Compound 4-E (yield: 70%) was synthesized in substantially the same manner as used to synthesize Intermediate Compound 1-E, except that Intermediate Compound 4-C was used instead of Intermediate Compound 1-C, and Intermediate Compound 3-D was used instead of Intermediate Compound 1-D.


Synthesis of Compound 52

Compound 52 (yield: 26%) was synthesized in substantially the same manner as used to synthesize Compound 1, except that Intermediate Compound 4-E was used instead of Intermediate Compound 1-E.





TABLE 1







Compound
H NMR (δ)
MS/FAB


Calc
found




1
8.74(d,1H), 8.56-8.55(m,4H), 8.08(d,1H), 7.94(m,1H), 7.57(d,1H), 7.41-7.16(m,11H), 7.00(m,1H), 1.32(s,9H)
790.20
790.20


2
8.95(s,1H), 8.74(d,1H), 8.57-8.55(m,3H), 8.08(d,1H), 7.86(d,1H), 7.57-6.98(m,12H), 1.43(s,9H), 1.32(s,9H)
846.26
846.26


51
8.58-8.55(m,6H), 7.57(d,2H), 7.32-7.27(m,12H), 7.03(d,2H)
773.15
773.15


52
8.57-8.55(m,6H), 7.57-7.51 (m,3H), 7.31-7.26(m, 10H), 7.04(s,1H), 7.00(d,1H), 1.33(s,9H)
829.21
829.21






Evaluation Example 1

LUMO and HOMO values of compounds of Synthesis Examples were measured using methods described in Table 2 below, and by using the Density Functional Theory (DFT) method of the Gaussian 09 program (where the structure optimization is performed at the level of the B3LYP hybrid functional, and 6-311 G(d,p) basis set), T1, dipole, and MLCT values of Compounds of Synthesis Examples were calculated. The results are shown in Table 3 below.





TABLE 2





HOMO energy level evaluation method
By using cyclic voltammetry (CV) (electrolyte: 0.1 M Bu4NPF6 / solvent: dimethylforamide (DMF) / electrode: 3-electrode system (working electrode: GC, reference electrode: Ag/AgCl, and auxiliary electrode: Pt)), the potential (V)-current (A) graph of each compound was obtained, and then, from the oxidation onset of the graph, the HOMO energy level of each compound was calculated.


LUMO energy level evaluation method
By using cyclic voltammetry (CV) (electrolyte: 0.1 M Bu4NPF6 / solvent: dimethylforamide (DMF) / electrode: 3-electrode system (working electrode: GC, reference electrode: Ag/AgCl, and auxiliary electrode: Pt)), the potential (V)-current (A) graph of each compound was obtained, and then, from the reduction onset of the graph, the LUMO energy level of each compound was calculated.









TABLE 3









Compound No.
HOMO (eV)
LUMO (eV)
T1 (nm)
Dipole (debye)

3MLCT (%)





1
-4.87
-1.52
458
6.573
16.72


2
-4.85
-1.45
457
6.458
16.83


51
-4.98
-1.26
445
4.969
18.71


52
-4.95
-1.20
443
4.835
18.88






Example 1

As an anode, a 15 Ω/cm2 (1200 Å) ITO glass substrate (available from Corning Co., Ltd) was cut to a size of 50 mm x 50 mm x 0.7 mm, sonicated in isopropyl alcohol and pure water for 5 minutes in each solvent, and cleaned by irradiation of ultraviolet rays and exposure of ozone thereto for 30 minutes, and the glass substrate was loaded onto a vacuum deposition apparatus.


2-TNATA, which is a commercially available compound, was vacuum-deposited on the substrate to form a hole injection layer having a thickness of 600 Å, and then, 4,4′-bis[N-(1-naphthyl)-N-phenylamino]biphenyl (hereinafter, referred to as NPB) as a hole transport compound was vacuum-deposited thereon to form a hole transport layer having a thickness of 300 Å.


Compound 1 (first compound), ETH2 (second compound), HTH29 (third compound) were vacuum-deposited on the hole transport layer to form an emission layer having a thickness of 400 Å. In this regard, an amount of Compound 1 is 10 wt% based on a total weight (100 wt%) of the emission layer, and a weight ratio of Compound ETH2 to Compound HTH29 was adjusted to 3 : 7.


Next, ETH2 was vacuum-deposited thereon to form a hole blocking layer having a thickness of 50 Å, Alq3 was deposited on the hole blocking layer to form an electron transport layer having a thickness of 300 Å, LiF as an alkali metal halide was deposited on the electron transport layer to form an electron injection layer having a thickness of 10 Å, and Al was vacuum-deposited thereon to form a cathode having a thickness of 3,000 Å, thereby completing manufacture of an organic electroluminescent device.




embedded image - 2-TNATA




embedded image - NPB




embedded image - ETH2




embedded image - HTH29


Examples 2 to 4 and Comparative Examples 1 and 2

Organic electroluminescent devices were manufactured in substantially the same manner as in Example 1, except that, in forming the emission layer, the first compound shown in Table 4 was used instead of Compound 1.


Evaluation Example 1

Driving voltage (V), luminescence efficiency (cd/A), maximum emission wavelength (nm), and device lifespan (T90) of organic electroluminescent devices according to Examples 1 to 4 and Comparative Examples 1 and 2 were each measured using a Keithley MU 236 and a luminance meter PR650, and the results are shown in Table 4 below. In Table 4, the driving voltage and the luminescence efficiency were driving voltage and luminescence efficiency at 10 mA/cm of current density, and the device lifespan (T90) is a measure of the time taken when the luminance reaches 90% of the initial luminance of 1,000 cd/m2.





TABLE 4











First compound
Luminance (cd/m2)
Driving Voltage Voltage (V)
Luminescence efficiency (cd/A)
Maximum emission wavelength (nm)
Device lifespan (h) (T90)




Example 1
1
1000
4.6
23.5
463
88


Example 2
2
1000
4.7
24.6
462
85


Example 3
51
1000
4.9
22.1
456
79


Example 4
52
1000
4.8
22.4
455
73


Comparative Example 1
CE1
1000
4.9
20.1
470
50


Comparative Example 2
CE2
1000
4.7
20.7
465
43








embedded image - 1




embedded image - 2




embedded image - 51




embedded image - 52




embedded image - CE1




embedded image - CE2


Referring to Table 4, it can be seen that the organic electroluminescent devices according to Examples 1 to 4 had improved luminescence efficiency and device lifespan, as compared to the organic electroluminescent devices according to Comparative Examples 1 and 2.


Examples 5 and 6 and Comparative Example 3

Organic light-emitting devices were manufactured in substantially the same manner as in Example 1, except that, in forming the emission layer, Compound 1 (first compound), Compound ETH2 (second compound), Compound HTH41 (third compound), and Compound DFD1 (fourth compound), which are shown in Table 5, were used instead of Compound 1 (first compound), Compound ETH2 (second compound), and Compound HTH29 (third compound). In this regard, an amount of the first compound was 10 wt% based on the total weight (100 wt%) of the emission layer, an amount of Compound DFD1 is 0.5 wt% based on the total weight (100 wt%) of the emission layer, and a weight ratio of Compound ETH2 to Compound HTH41 was adjusted to 3 : 7.




embedded image - HTH41




embedded image - DFD1


Evaluation Example 2

Driving voltage (V), luminescence efficiency (cd/A), maximum emission wavelength (nm), and device lifespan (T90) of organic electroluminescent devices according to Examples 5 and 6 and Comparative Example 3 were each measured using a Keithley MU 236 and a luminance meter PR650, and the results are each shown in Table 5. In Table 5, the driving voltage and the luminescence efficiency were driving voltage and luminescence efficiency at 10 mA/cm of current density, and the device lifespan (T90) is a measure of the time taken when the luminance reaches 90% of the initial luminance of 1,000 cd/m2.





TABLE 5











First compound
Luminance (cd/m2)
Driving Voltage Voltage (V)
Efficiency (cd/A)
Maximum emission wavelength (nm)
Device lifespan (h) (T90)




Example 5
1
1000
4.5
20.5
460
96


Example 6
2
1000
4.6
18.6
460
90


Comparative Example 3
CE1
1000
4.7
16.3
461
53








embedded image - 1




embedded image - 2




embedded image - CE1


Referring to Table 5, it can be seen that the organic electroluminescent devices according to Examples 5 and 6 exhibited high luminescence efficiency and color conversion efficiency in a blue emission wavelength region and had excellent device lifespan, as compared to the organic electroluminescent device according to Comparative Example 3.


A light-emitting device having high efficiency and long lifespan and a high-quality electronic apparatus including the same may be manufactured by using the organometallic compound.


It should be understood that embodiments described herein should be considered in a descriptive sense only and not for purposes of limitation. Descriptions of features or aspects within each embodiment should typically be considered as available for other similar features or aspects in other embodiments. While one or more embodiments have been described with reference to the figures, it will be understood by those of ordinary skill in the art that various changes in form and details may be made therein without departing from the spirit and scope of the present disclosure as defined by the following claims, and equivalents thereof.

Claims
  • 1. A light-emitting device comprising: a first electrode;a second electrode facing the first electrode; andan interlayer between the first electrode and the second electrode and including an emission layer,wherein the emission layer comprises an organometallic compound represented by Formula 1-1 or 1-2: wherein, in Formulae 1-1 and 1-2,M is platinum (Pt), palladium (Pd), copper(Cu), silver (Ag), gold (Au), rhodium (Rh), ruthenium (Ru), osmium (Os), titanium (Ti), zirconium (Zr), hafnium (Hf), europium (Eu), terbium (Tb), or thulium (Tm),ring CY1 to ring CY3 are each independently a C5-C30 carbocyclic group or a C1-C30 heterocyclic group,X1 to X3 are each independently C or N,X21 is C,Y1 is C(Z1) or N,Y2 is C(Z2) or N,Y3 is C(Z3) or N,Y4 is C(Z4) or N,Y5 is C(Z5) or N,Y6 is C(Z6) or N,Y7 is C(Z7) or N,Y8 is C(Z8) or N,L1 to L3 are each independently a single bond, *—C(R1a)(R1b)—*’, *—C(R1a)═*’, *═C(R1a)—*’, *—C(R1a)═C(R1b)—*’, *—C(═O)—*’, *—C(═S)—*’, *—C≡C—*’, *—B(R1a)—*’, *—N(R1a)—*’, *—O—*’, *—P(R1a)—*’, *—Si(R1a)(R1b)—*’, *—P(═O)(R1a)—*’, *—S—*’, *—S(═O)—*’, *—S(═O)2—*’, or *—Ge(R1a)(R1b)—*’, and * and *’ each indicate a binding site to a neighboring atom,n1 to n3 are each independently an integer from 1 to 5,R1 to R3, Z1 to Z8, R1a and R1b are each independently hydrogen, deuterium, —F, —Cl,Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C60 alkyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkenyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkynyl group unsubstituted or substituted with at least one R10a, a C1-C60 alkoxy group unsubstituted or substituted with at least one R10a, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, a C6-C60 aryloxy group unsubstituted or substituted with at least one R10a, a C6-C60 arylthio group unsubstituted or substituted with at least one R10a, —C(Q1)(Q2)(Q3), —Si(Q1)(Q2)(Q3), —N(Q1)(Q2), —B(Q1)(Q2), —C(═O)(Q1), —S(═O)2(Q1), or —P(═O)(Q1)(Q2),a1 to a3 are each independently an integer from 0 to 10, in Formulae 1-1 and 1-2 indicates a single bond or a double bond,Z1 and Z2 are optionally bonded together to form a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,Z3 and Z4 are optionally bonded together to form a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,Z5 and Z6 are optionally bonded together to form a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,Z7 and Z8 are optionally bonded together to form a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,R10a is: deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, or a nitro group;a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, or a C1-C60 alkoxy group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C3-C60 carbocyclic group, a C1-C60 heterocyclic group, a C6-C60 aryloxy group, a C6-C60 arylthio group, —Si(Q11)(Q12)(Q13), —N(Q11)(Q12), —B(Q11)(Q12), —C(═O)(Q11), —S(═O)2(Q11), —P(═O)(Q11)(Q12), or any combination thereof;a C3-C60 carbocyclic group, a C1-C60 heterocyclic group, a C6-C60 aryloxy group, or a C6-C60 arylthio group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a C3-C60 carbocyclic group, a C1-C60 heterocyclic group, a C6-C60 aryloxy group, a C6-C60 arylthio group, —Si(Q21)(Q22)(Q23), —N(Q21)(Q22), —B(Q21)(Q22), —C(═O)(Q21), —S(═O)2(Q21), —P(═O)(Q21)(Q22), or any combination thereof; or—Si(Q31)(Q32)(Q33), —N(Q31)(Q32), —B(Q31)(Q32), —C(═O)(Q31), —S(═O)2(Q31), or —P(═O)(Q31)(Q32), andQ1 to Q3, Q11 to Q13, Q21 to Q23, and Q31 to Q33 are each independently: hydrogen; deuterium; —F; —Cl; —Br; —I; a hydroxyl group; a cyano group; a nitro group; a C1-C60 alkyl group; a C2-C60 alkenyl group; a C2-C60 alkynyl group; a C1-C60 alkoxy group; or a C3-C60 carbocyclic group or a C1-C60 heterocyclic group, each unsubstituted or substituted with deuterium, —F, a cyano group, a C1-C60 alkyl group, a C1-C60 alkoxy group, a phenyl group, a biphenyl group, or any combination thereof.
  • 2. The light-emitting device of claim 1, wherein the first electrode is an anode, the second electrode is a cathode,the interlayer further comprises a hole transport region between the first electrode and the emission layer and an electron transport region between the emission layer and the second electrode,the hole transport region comprises a hole injection layer, a hole transport layer, an emission auxiliary layer, an electron blocking layer, or any combination thereof, andthe electron transport region comprises a hole blocking layer, an electron transport layer, an electron injection layer, an electron control layer, or any combination thereof.
  • 3. The light-emitting device of claim 1, wherein the interlayer comprises: i) a first compound which is an organometallic compound represented by Formula 1-1 or 1-2; andii) a second compound including at least one π electron-deficient nitrogen-containing C1-C60 cyclic group, a third compound including a π electron-rich C3-C60 cyclic group or a pyridine group, a fourth compound capable of emitting delayed fluorescence, or any combination thereof,the first compound, the second compound, the third compound, and the fourth compound are different from each other, andthe third compound does not include Compound CBP or Compound mCBP: .
  • 4. The light-emitting device of claim 3, wherein the second compound comprises a compound represented by Formula 2: wherein, in Formula 2,L61 to L63 are each independently a single bond, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,b61 to b63 are each independently an integer from 1 to 5,X64 is N or C(R64), X65 is N or C(R65), X66 is N or C(R66), and at least one of X64 to X66 is N,R61 to R66 are each independently hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C60 alkyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkenyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkynyl group unsubstituted or substituted with at least one R10a, a C1-C60 alkoxy group unsubstituted or substituted with at least one R10a, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, a C6-C60 aryloxy group unsubstituted or substituted with at least one R10a, a C6-C60 arylthio group unsubstituted or substituted with at least one R10a, —C(Q1)(Q2)(Q3), —Si(Q1)(Q2)(Q3), —N(Q1)(Q2), —B(Q1)(Q2), —C(═O)(Q1), —S(═O)2(Q1), or —P(═O)(Q1)(Q2), andR10a and Q1 to Q3 are respectively the same as those defined with respect to Formulae 1-1 and 1-2.
  • 5. The light-emitting device of claim 3, wherein the third compound comprises a group represented by Formula 3: wherein ring CY71 and ring CY72 in Formula 3 are each independently a π electron-rich C3-C60 cyclic group or a pyridine group,X71 in Formula 3 is a single bond, or a linking group including O, S, N, B, C, Si, or any combination thereof, and* in Formula 3 indicates a binding site to a neighboring atom in the third compound.
  • 6. The light-emitting device of claim 3, wherein the fourth compound is a compound including at least one cyclic group including boron (B) and nitrogen (N) as ring-forming atoms.
  • 7. An electronic apparatus comprising the light-emitting device according to claim 1.
  • 8. The electronic apparatus of claim 7, further comprising a thin-film transistor, wherein thin-film transistor comprises a source electrode and a drain electrode, andthe first electrode of the light-emitting device is electrically connected to at least one selected from the source electrode and the drain electrode of the thin-film transistor.
  • 9. The electronic apparatus of claim 7, further comprising a color filter, a quantum dot color conversion layer, a touch screen layer, a polarizing layer, or any combination thereof.
  • 10. An organometallic compound represented by Formula 1-1 or 1-2: wherein, in Formulae 1-1 and 1-2,M is platinum (Pt), palladium (Pd), copper(Cu), silver (Ag), gold (Au), rhodium (Rh), ruthenium (Ru), osmium (Os), titanium (Ti), zirconium (Zr), hafnium (Hf), europium (Eu), terbium (Tb), or thulium (Tm),ring CY1 to ring CY3 are each independently a C5-C30 carbocyclic group or a C1-C30 heterocyclic group,X1 to X3 are each independently C or N,X21 is C,Y1 is C(Z1) or N,Y2 is C(Z2) or N,Y3 is C(Z3) or N,Y4 is C(Z4) or N,Y5 is C(Z5) or N,Y6 is C(Z6) or N,Y7 is C(Z7) or N,Y8 is C(Z8) or N,L1 to L3 are each independently a single bond, *—C(R1a)(R1b)—*’, *—C(R1a)═*’, *═C(R1a)—*’, *—C(R1a)═C(R1b)—*’, *—C(═O)—*’, *—C(═S)—*’, *—C≡C—*’, *—B(R1a)—*’, *—N(R1a)—*’, *—O—*’, *—P(R1a)—*’, *—Si(R1a)(R1b)—*’, *—P(═O)(R1a)—*’, *—S—*’, *—S(═O)—*’, *—S(═O)2—*’, or *—Ge(R1a)(R1b)—*’, and * and *’ each indicate a binding site to a neighboring atom,n1 to n3 are each independently an integer from 1 to 5,R1 to R3 and Z1 to Z8 are each independently hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C60 alkyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkenyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkynyl group unsubstituted or substituted with at least one R10a, a C1-C60 alkoxy group unsubstituted or substituted with at least one R10a, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, a C6-C60 aryloxy group unsubstituted or substituted with at least one R10a, a C6-C60 arylthio group unsubstituted or substituted with at least one R10a, —C(Q1)(Q2)(Q3), —Si(Q1)(Q2)(Q3), —N(Q1)(Q2), —B(Q1)(Q2), —C(═O)(Q1), —S(═O)2(Q1), or —P(═O)(Q1)(Q2),a1 to a3 are each independently an integer from 0 to 10,in Formulae 1-1 and 1-2 indicates a single bond or a double bond,Z1 and Z2 are optionally bonded together to form a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,Z3 and Z4 are optionally bonded together to form a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,Z5 and Z6 are optionally bonded together to form a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,Z7 and Z8 are optionally bonded together to form a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a or a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a,R10a is: deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, or a nitro group;a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, or a C1-C60 alkoxy group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C3-C60 carbocyclic group, a C1-C60 heterocyclic group, a C6-C60 aryloxy group, a C6-C60 arylthio group, —Si(Q11)(Q12)(Q13), —N(Q11)(Q12), —B(Q11)(Q12), —C(═O)(Q11), —S(═O)2(Q11), —P(═O)(Q11)(Q12), or any combination thereof;a C3-C60 carbocyclic group, a C1-C60 heterocyclic group, a C6-C60 aryloxy group, or a C6-C60 arylthio group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C60 alkyl group, a C2-C60 alkenyl group, a C2-C60 alkynyl group, a C1-C60 alkoxy group, a C3-C60 carbocyclic group, a C1-C60 heterocyclic group, a C6-C60 aryloxy group, a C6-C60 arylthio group, —Si(Q21)(Q22)(Q23), —N(Q21)(Q22), —B(Q21)(Q22), —C(═O)(Q21), —S(═O)2(Q21), —P(═O)(Q21)(Q22), or any combination thereof; or—Si(Q31)(Q32)(Q33), —N(Q31)(Q32), —B(Q31)(Q32), —C(═O)(Q31), —S(═O)2(Q31), or —P(═O)(Q31)(Q32), andQ1 to Q3, Q11 to Q13, Q21 to Q23, and Q31 to Q33 are each independently: hydrogen; deuterium; —F; —Cl; —Br; —I; a hydroxyl group; a cyano group; a nitro group; a C1-C60 alkyl group; a C2-C60 alkenyl group; a C2-C60 alkynyl group; a C1-C60 alkoxy group; or a C3-C60 carbocyclic group or a C1-C60 heterocyclic group, each unsubstituted or substituted with deuterium, —F, a cyano group, a C1-C60 alkyl group, a C1-C60 alkoxy group, a phenyl group, a biphenyl group, or any combination thereof.
  • 11. The organometallic compound of claim 10, wherein a group represented by in Formulae 1-1 and 1-2 is any one of groups represented by Formulae CY1(1) to CY1(20):wherein, in Formulae CY1(1) to CY1(20),R11 to R13 are each independently deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C60 alkyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkenyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkynyl group unsubstituted or substituted with at least one R10a, a C1-C60 alkoxy group unsubstituted or substituted with at least one R10a, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, a C6-C60 aryloxy group unsubstituted or substituted with at least one R10a, a C6-C60 arylthio group unsubstituted or substituted with at least one R10a, —C(Q1)(Q2)(Q3), —Si(Q1)(Q2)(Q3), —N(Q1)(Q2), —B(Q1)(Q2), —C(═O)(Q1), —S(═O)2(Q1), or —P(═O)(Q1)(Q2),*, *’, and *” each indicate a binding site to a neighboring atom, andX1, R10a, and Q1 to Q3 are respectively the same as those described in claim 10.
  • 12. The organometallic compound of claim 10, wherein a group represented by in Formulae 1-1 and 1-2 is any one of groups represented by Formulae CY2(1) to CY2(11):wherein, in Formulae CY2(1) to CY2(11),b1 is an integer from 0 to 3,b2 is an integer from 0 to 2,b3 is an integer from 0 to 6,b4 is an integer from 0 to 5,*, *’, and *” each indicate a binding site to a neighboring atom, andX2 and R2 are respectively the same as those described in claim 10.
  • 13. The organometallic compound of claim 10, wherein a group represented by in Formula 1-1 is any one of groups represented by Formulae CY3(1) to CY3(14):wherein, in Formulae CY3(1) to CY3(14),R31 to R34 are each independently deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C60 alkyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkenyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkynyl group unsubstituted or substituted with at least one R10a, a C1-C60 alkoxy group unsubstituted or substituted with at least one R10a, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, a C6-C60 aryloxy group unsubstituted or substituted with at least one R10a, a C6-C60 arylthio group unsubstituted or substituted with at least one R10a, —C(Q1)(Q2)(Q3), —Si(Q1)(Q2)(Q3), —N(Q1)(Q2), —B(Q1)(Q2), —C(═O)(Q1), —S(═O)2(Q1), or —P(═O)(Q1)(Q2),* and *’ each indicate a binding site to a neighboring atom, andR10a and Q1 to Q3 are respectively the same as those described in claim 10.
  • 14. The organometallic compound of claim 10, wherein a group represented by in Formulae 1-1 and 1-2 is any one of groups represented by Formulae CYN(1) to CYN(21):wherein, in Formulae CYN(1) to CYN(21),Z11 to Z16 are each independently deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a C1-C60 alkyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkenyl group unsubstituted or substituted with at least one R10a, a C2-C60 alkynyl group unsubstituted or substituted with at least one R10a, a C1-C60 alkoxy group unsubstituted or substituted with at least one R10a, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, a C1-C60 heterocyclic group unsubstituted or substituted with at least one R10a, a C6-C60 aryloxy group unsubstituted or substituted with at least one R10a, a C6-C60 arylthio group unsubstituted or substituted with at least one R10a, —C(Q1)(Q2)(Q3), —Si(Q1)(Q2)(Q3), —N(Q1)(Q2), —B(Q1)(Q2), —C(═O)(Q1), —S(═O)2(Q1), or —P(═O)(Q1)(Q2),b15 and b16 are each independently an integer from 0 to 4,Y11 to Y18 are each independently C or N, andR10a and Q1 to Q3 are respectively the same as those described in claim 10.
  • 15. The organometallic compound of claim 14, wherein Z11 to Z16 are each independently deuterium, —F, —Cl, —Br, —I, a cyano group, a C1-C60 alkyl group unsubstituted or substituted with at least one R10a, a C3-C60 carbocyclic group unsubstituted or substituted with at least one R10a, or —Si(Q1)(Q2)(Q3), and R10a and Q1 to Q3 are respectively the same as those defined with respect to Formulae 1-1 and 1-2.
  • 16. The organometallic compound of claim 10, wherein L1 and L3 are each a single bond, and L2 is *—O—*’ or *—S—*’.
  • 17. The organometallic compound of claim 10, wherein R1 to R3 are each independently: a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a 2-methylbutyl group, a 2,2-dimethylpropyl group, a 1-ethylpropyl group, or a 1,2-dimethylpropyl group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, or a nitro group; ora phenyl group, a biphenyl group, a naphthyl group, a phenanthrenyl group, an anthracenyl group, a carbazolyl group, or a 9,10-dihydroacridinyl group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, a methyl group, an ethyl group, an n-propyl group, an iso-propyl group, an n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a 2-methylbutyl group, a 2,2-dimethylpropyl group, a 1-ethylpropyl group, a 1,2-dimethylpropyl group, a phenyl group, or any combination thereof.
  • 18. The organometallic compound of claim 10, wherein the C3-C60 carbocyclic groups and the C1-C60 heterocyclic groups each comprise a 6-membered ring.
  • 19. The organometallic compound of claim 10, wherein the organometallic compound has a triplet metal to ligand charge transfer (3MLCT) value 10% or more.
  • 20. The organometallic compound of claim 10, wherein the organometallic compound represented by Formula 1-1 or 1-2 is any one of Compounds 1 to 80: .
Priority Claims (1)
Number Date Country Kind
10-2021-0152569 Nov 2021 KR national